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Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder 
affecting the elderly population of the world. With the rise in the socio-economic 
burden caused by the increase in its incidence, potential novel targets for effective AD 
therapeutics are urgently needed. While the precise molecular mechanisms underlying 
the disease pathology is poorly understood, several approaches have been proposed to 
mitigate the effects of this devastating disorder. The overall goal of this thesis is thus 
to identify and explore potential novel targets for therapeutic intervention in AD. In 
line with our goal, we employed two different approaches in our study. In the first 
part, we evaluated the synergy between two biological enzymes in enhancing 
neuroprotection, whereas in the second part we focussed on elucidating the 
neuroprotective mechanism of a dietary supplement using metabonomics in an AD 
cell model.  
 
In the first part of this thesis, we studied the co-influence of DHFR inhibition on 
GSK-3β inhibitory effects in modulating the multiple pathological pathways of AD.  
Using SH-SY5Y neuroblastoma cells and RAW264.7 mouse macrophage cells as our 
AD cell models, we evaluated the effect of DHFR inhibition, either through the small 
molecule inhibitor methotrexate or small interfering RNA (siRNA), on the 
neuroprotective effects of GSK-3β specific inhibitor, 6’-bromoindirubin-3’-oxime.  
Dual luciferase and western blot analyses showed that DHFR inhibition synergized 
with GSK-3β inhibition in enhancing the activities of β-catenin protein and its 
downstream target, Axin-2. We observed an increase in the inhibitory 
phosphorylation of GSK-3β at Serine9 position and a subsequent decrease in tau 
hyperphosphorylation. DHFR inhibition also augmented the anti-inflammatory 
responses of GSK-3β inhibition by decreasing the release of nitric oxide, reactive 
oxygen species and TNF-α in lipopolysaccharide-stimulated RAW264.7 macrophage 
xvi 
 
cells. Lastly, the dual enzyme inhibition strategy was observed to significantly 
improve SH-SY5Y cell survival against hydrogen peroxide insults. 
 
For the second half of this thesis, we evaluated the neuroprotective mechanism of 
docosahexaenoic acid (DHA), a dietary supplement, in mitigating metabolic 
perturbations in AD.  Gas chromatography mass spectrometry based global and 
targeted metabonomic approaches were used to elucidate the metabolic phenotypes 
associated with DHA therapy in lysate and supernatant samples of Chinese hamster 
ovary (CHO) wild type and APP-associated cells. Our results reported distinct 
metabolites associated with DHA-treated and control groups in multivariate data 
analysis. A list of statistically significant marker metabolites that characterized the 
metabotypes associated with DHA treatment was further identified and showed 
increase in levels of succinic acid, citric acid, malic acid, docosahexaenoic acid, 
fructose, 3-phosphoglycerate and glycine and decrease in levels of zymosterol, 
cholestadiene, cholesterol and arachidonic acid. Upon subsequent pathway analysis 
these metabolites were found to correlate with glucose metabolism, tricarboxylic acid 
cycle, cholesterol biosynthesis pathway and fatty acid metabolism. A follow-up 
targeted study on the cholesterol metabolism revealed the beneficial effects of DHA 
in regulating the cholesterol metabolism pathway by a mechanism very similar to 
statins.   
 
In conclusion, our findings not only provided the therapeutic benefit of modulating 
GSK-3β activity using DHFR enzyme, but also provided the mechanistic 
understanding for the neuroprotective benefits of DHA in AD. With further 
characterization and studies, both of these approaches may be further explored as a 
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CHAPTER 1:  INTRODUCTION 
 
1.1 Alzheimer’s disease: An overview 
Alzheimer’s disease (AD) is an age-related, irreversible, chronic neurodegenerative 
disorder caused by the death of neurons in several areas of the brain responsible 
mainly for, but not limited to, memory, cognition and behavior. AD accounts for 
approximately 60-80% of the dementia cases in the elderly [1] and is considered as 
the most common type of dementia affecting the aging population. The alarming rate 
of AD incidence is posing as a serious public health concern throughout the world. It 
is the sixth leading cause of death in the United States of America [2] with an 
estimated 5.2 million people affected in 2013 [1]. In the Asia Pacific region, it is 
estimated that the dementia-affected population will increase from 13.7 million 
people in 2005 to 64.6 million by 2050, with the number of new cases increasing 
from 4.3 million per year in 2005 to 19.7 million by 2050 [3]. 
 
Before 2011, AD was classified mainly into three stages: mild, moderate and severe 
AD. However, with the implementation of new criteria and guidelines for early 
detection and diagnosis of AD by the National Institute of Ageing (NIA) and the 
Alzheimer’s Association in 2011 [1], AD is now classified as preclinical AD, mild 
cognitive impairment (MCI) due to AD and dementia due to AD.  According to these 
new guidelines, preclinical AD or MCI is defined as the stage with early brain 
changes preceding the development of symptoms whereas dementia due to AD is 
defined for individuals with already developed symptoms and encompassing all the 
stages from mild to moderate to severe AD. The progression of AD through these 
various stages may occur at different rate in different individuals, but the most 
common symptomatic pattern begins with difficulty and gradual worsening in 
remembering and retaining new information. Cognitive decline, amnesia, inability to 
recognize people and places, impaired ability of reasoning or judgment, increased 
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agitation, hallucinations and delusions are few of the prominent symptoms 
experienced by AD patients. The disease is progressive in nature, with symptoms 
gradually worsening over time. The individual becomes completely dependent on the 
support of a caretaker for carrying out his simple daily life activities in the most 
advanced stages. Unfortunately, the current diagnosis options, mainly clinical, 
neuropsychological and neuroimaging assessments, are only effective in confirming 
the disease in very advanced states and there is an urgent need for developing newer 
techniques to enable earlier diagnosis of AD in the pre-symptomatic stages.  
  
The exact cause of neurodegeneration in AD is still unknown, although it is believed 
to be a mix of genetic, environmental and lifestyle-related factors. So far, several 
hypotheses have been proposed to explain the molecular mechanisms underlying AD 
pathology, but none of them have been completely proven. Despite the unknown 
etiology, the three most important pathophysiological hallmarks characterizing AD 
are the presence of extracellular neuritic plaques of amyloid beta (Aβ) peptide, 
intracellular accumulation of neurofibrillary tangles (NFTs) composed of 
hyperphosphorylated tau proteins and reactive gliosis [4]. Aβ plaques and tangles are 
said to interfere with the communication of neurons at synapses and block the 
transport of essential nutrients in and out of the neuronal cells, causing the cells to 
slowly lose their ability to function properly and die [1]. In addition, these plaques 
and tangles stimulate glial cells, causing them to secrete inflammatory cytokines and 
oxidative stress mediators, which in turn affect the survival of the surrounding 
neuronal cells [5]. As a result, the affected areas of the brain begin to drastically 
shrink in size and there is widespread accumulation of debris arising from dead and 




Figure 1.1: Abnormal pathological characteristic of Alzheimer’s disease. The medical 




1.2 Molecular mechanisms involved in AD progression and 
neurodegeneration 
In order to develop novel and effective therapeutic strategies for overall AD 
management, the identification of the underlying molecular mechanisms is key. 
Unfortunately this knowledge is relatively poor, although it has been proposed to 
involve an interplay of multiple factors, namely, mitochondrial dysfunction, 
inflammation, oxidative stress, neuronal cell loss and NFT formation, rather than a 
single cause. Several competing hypotheses have been put forward for explaining the 
cause of the disease as shown in Figure 1.2. Amongst the various hypotheses, the 
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amyloid cascade, cholinergic, inflammatory and tau tangle hypotheses are the most 
widely accepted ones. Each of the hypotheses discussed below has mounting 
evidence to support their claims; nonetheless, several questions have been raised on 
the validity of each one of them. In addition, none of the hypotheses stands complete 
on their own and they are not mutually exclusive. 
 
Figure 1.2: Various proposed hypotheses for AD pathogenesis 
 
1.2.1 Cholinergic hypothesis 
The loss of cholinergic neurotransmission in the central nervous system has been 
reported to cause significant deterioration of cognitive functions in AD patients [7,8]. 
Based on this hypothesis, cholinergic replacement therapy carried out by either 
increasing the synthesis of acetylcholine (ACh) or by reducing ACh breakdown with 
acetylcholinesterase inhibitors (AChEIs) has been used for improving cognitive 
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functions in AD patients. Tacrine, donepezil, rivastigmine and galantamine are some 
of the approved AChEIs currently used for clinical treatment of AD patients. 
 
1.2.2 Amyloid cascade hypothesis 
The amyloid cascade hypothesis [9-12] is based on the postulation that amyloid 
deposition in the brain is the predominant precursor for the widespread 
neurodegeneration observed in AD brains. Point mutations in the amyloid precursor 
protein (APP), presenilin 1 and 2 (PS-1 and PS-2) genes [13,14] cause abnormal 
proteolytic processing of APP to insoluble Aβ fragments, depositing as Aβ plaques in 
the extra-neuronal area. Once formed, these Aβ plaques induce secretion of 
inflammatory cytokines from glial cells, propagate NFT formation [15] and induce 
hypometabolism in neuronal cells [16-19], ultimately leading to neuronal cell death. 
However, the recent failure of Aβ-only directed therapeutic approaches has raised 
several questions on the validity of this hypothesis as the primary driving mechanism 
for AD pathology. 
 
1.2.3 Inflammation and oxidative stress hypothesis 
This hypothesis stemmed from the free radical hypothesis of aging which proposed 
that age-related neurodegenerative diseases mainly develop from the imbalance 
between the generation and removal of free radicals and reactive oxygen species 
(ROS) in brain cells [20]. Once formed, ROS activate nuclear factor kappa B (NF-
κB) in microglial and astrocyte cells, stimulating them to release different 
inflammatory cytokines and cytotoxic substances, leading to establishment of chronic 
inflammation and neurodegeneration in AD brain. In addition, increased expression 
of inflammatory cytokines and oxidative stress mediators has been shown to induce 
Aβ deposition and senile plaque formation in neuronal cells [21,22] and transform 
non-aggregated Aβ into aggregated forms in vitro [23].  
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1.2.4 Tau tangle hypothesis   
Abnormal folding and aggregation of the normal microtubule-associated tau proteins 
has been considered as one of the causative agents leading to AD development. 
Hyperphosphorylation of the tau proteins causes them to accumulate as paired helical 
filaments and aggregate as NFTs inside neuronal cells. These NFTs then disintegrate 
the cell’s transport system and damage axonal communication between the cells, 
eventually leading to neuronal cell loss. Over the years, NFTs are increasingly being 
considered as independent neuron damaging agents rather than a downstream 
consequence of Aβ toxicity and hence, several tau-directed and tau-modifying 
strategies are being developed to alter AD outcome or progression. 
 
1.2.5 Mitochondrial dysfunction hypothesis 
One of the consistently detected dysfunctions in the brains of AD patients is 
alterations in the activity of the electron transport chain (ETC) and impairment in the 
functioning of tricarboxylic acid cycle (TCA) enzymes. These deregulations cause a 
decrease in the production of ATP molecules, establish a state of hypometabolism in 
neuronal cells and induce oxidative stress by lowering the respiration rate and 
increasing the generation of ROS molecules [24-26]. Moreover, this hypothesis 
proposes that toxin-induced mitochondrial anomalies aggravate APP expression and 
processing of APP to Aβ in sporadic late-onset AD [27,28].  
 
1.2.6 Cholesterol hypothesis 
The role of cholesterol in the pathology of AD was brought forward by the 
identification of mutations in cholesterol transporter protein coding gene, 
apolipoprotein E (ApoE), and hypercholesterolemia as risk factors for AD [29]. Of 
the three allele of ApoE gene, allele ε4 has been associated with elevated cholesterol 
levels and an increased risk of developing AD by many studies [30-32]. The 
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contribution of increased intracellular cholesterol level in AD pathology is discussed 
in further detail in Chapter 5. 
 
1.3 Drug targets for AD therapeutics 
Based on the abovementioned hypotheses, various drug targets and strategies are 
currently being evaluated for their therapeutic potential in AD. Several AChEIs, 
muscarinic and nicotinic-cholinergic ligands are being developed to boost the 
cholinergic neurotransmission following on the lines of clinically approved AChEIs 
for AD treatment [33]. However, the entire drug development process in AD 
therapeutics is largely focussed on the two pathological hallmarks of the disease: Aβ 
and NFTs. The anti-amyloid targeted therapies are mainly divided into three classes 
[34]: 1) α-secretase activators, γ-secretase modulators and β-secretase inhibitors to 
reduce Aβ production; 2) Aβ aggregation inhibitors; and 3) anti-amyloid 
immunotherapy to increase Aβ clearance.  Similarly, tau-directed therapeutics are 
based either on modulating tau phosphorylation using tau-phosphorylating kinase 
inhibitors or inhibiting tau aggregation and/or promoting disassembly of the formed 
aggregates.  
 
Different steroidal and non-steroidal anti-inflammatory drugs, anti-oxidants, free 
radical scavengers, cyclooxygenase inhibitors and peroxisome proliferator activated 
receptor-γ agonists are being evaluated to counteract the inflammation and oxidative 
stress-mediated damages in AD [35]. Based on the cholesterol hypothesis, cholesterol 
lowering agents called statins are being evaluated to target hypercholesterolemia and 
protect against Aβ-induced damages. Apart from the protein-focussed strategies that 
currently dominate AD research, targeting of organelles, particularly mitochondria, is 
also an emerging approach in AD therapy. These mitochondria-protecting agents 
either increase the mitochondrial membrane potential or inhibit mitochondrial 
transition pore to improve neuronal survival [36]. Besides the abovementioned 
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strategies, glycogen synthase kinase-3 (GSK-3) enzyme has emerged as a pivotal 
target involved in the regulation of different neuropathological hallmarks of AD and 
is discussed in detail in the following section. 
 
Glycogen synthase kinase-3 - a pleiotropic target 
Emerging studies have implicated GSK-3, a serine/threonine protein kinase, as a key 
mediator deeply involved in the fundamental mechanism of various hypotheses 
culminating in both the sporadic and familial forms of AD [37-40]. The two isoforms 
of GSK-3, GSK-3α and GSK-3β, are important for normal development, neuronal 
growth and differentiation, metabolic homeostasis, cell polarity, cell fate. Aberrant 
activation of GSK-3 enzymes has been proven to: 1) form multi-protein complexes 
with PS-1 that inactivates Wnt/β-catenin signaling pathway causing degradation of β-
catenin protein and leading to neuronal cell loss by reducing the transcription of 
downstream Wnt proliferative genes [41,42]; 2) hyperphosphorylate tau proteins and 
promote its aggregation into NFTs [43,44]; 3) induce inflammatory processes by 
regulating the NF-kB activity [45,46]; 4) cause deficits in long-term potentiation, 
synaptic plasticity, spatial learning and memory [47-50]; 5) induce apoptosis [51]; 
and 6) regulate APP cleavage and formation of Aβ peptides and ensuing toxicity 
[52,53]. Figure 1.3 briefly depicts GSK-3’s pleiotropic involvement in various 
pathological cascades of AD.  
 
Owing to its pleotropic involvement in the multiple pathophysiological cascades in 
AD, inhibiting GSK-3 activity via pharmacological intervention has thus emerged as 
an important strategy for managing AD. Likewise, GSK-3 inhibition with small 
molecule inhibitors has been shown to provide protection against Aβ-mediated toxic 
damages, reduce NFT levels, increase β-catenin levels and enhance neuronal survival 




Figure 1.3: Pleiotropic involvement of GSK-3 in various pathological cascades of AD. 
 
The eminent benefit exhibited by GSK-3 inhibition in AD management has 
encouraged the development of selective and potent GSK-3 inhibitors for use as AD 
therapeutics. However, no effective therapeutic outcomes have emerged from using 
GSK-3 inhibitors, mainly due to the limited specificity and high toxicity of these 
agents. Therefore, there is a need for identifying additional pathway regulators for 
modifying and enhancing the therapeutic efficacy of currently available GSK-3 
inhibitors for AD therapeutics.  In the first part of this thesis, we thus attempt to 
address this gap by evaluating the novel interaction between folate metabolism and 
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GSK-3 signaling pathway to enhance the neuroprotective and anti-inflammatory 
effects of a GSK-3 inhibitor and it is discussed further in Chapter 3.  
 
1.4 Alternative treatment approaches 
Many clinical and experimental studies are ongoing for developing disease-modifying 
agents for AD. However, the disappointing results of the numerous clinical trials [33] 
have greatly limited the therapeutic pool available for treating AD. This lack of 
availability of conventional pharmacological approaches has renewed interest in the 
use of complementary and alternative treatment methods for AD management. The 
basis for the use of nutritional and dietary supplements arises from the connection of 
AD with mitochondrial energy deficits and lipid metabolism imbalances giving rise to 
oxidative stress and ultimately neuronal cell death. Thus, dietary manipulations are 
proposed to enhance cognitive abilities and counteract neuronal energy deficits for 
slowing down AD progression.  
 
Although the safety and efficacy of these alternative treatment forms are debatable, 
some of the products are already available in the market as medical food or have 
entered clinical trials to gather scientific evidence for their usage. Accordingly, 
vitamins, natural anti-oxidants, caprylic acid, phosphatidylserine and polyunsaturated 
fatty acids (PUFAs) have emerged as therapeutic agents being tested for managing 
AD. The beneficial role of these nutritional agents in managing or delaying the 
symptoms of AD has been shown in numerous in vitro and in vivo experiments, 
however, the results of the epidemiological studies have been mostly a mix of 
positive and negative outcomes [58]. For example, laboratory studies with natural 
anti-oxidant vitamin E have shown protection from oxidation and inflammation-
mediated damages in AD animals [59]. However, different epidemiological studies 
have reported conflicting results regarding the association between higher vitamin 
intake and lower risk of AD development [60-63]. 
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Amongst other dietary supplements, PUFAs have been widely studied for their 
therapeutic effects in neurodegenerative diseases due to their role in maintaining 
neuronal functions and brain development. PUFAs are bioactive molecules with 
diverse physiological functions ranging from contribution in cell structure to signal 
transduction. The omega-3 (ω-3) PUFAs, namely docosahexaenoic acid (DHA), 
eicosapentaenoic acid (EPA) and α-linoleic acid (ALA), have been reported to have 
beneficial effects in AD, with large-scale epidemiological studies reporting their 
consumption to reduce the risk of development, cognitive impairment and cognitive 
decline in AD [64,65]. Amongst the different ω-3 PUFAs, greater interest has been 
given to studying DHA as it is found to be the most abundant in the mammalian 
brain, constituting about 8% of the dry weight of the brain [66]. DHA plays a key role 
in memory, neuroprotection and vision and displays inflammation-resolving 
properties [67]. Owing to its involvement in a number of physiological functions, 
DHA has been used to treat a variety of conditions such as heart diseases, diabetes, 
cancer, neurodegeneration and inflammatory conditions. In AD, DHA levels have 
been found to be significantly decreased in serum and neuronal membranes of 
patients as compared to healthy controls [68,69], suggesting a possible role of DHA 
in the intervention of AD. Based on the same hypothesis, several studies have been 
conducted to evaluate the neuroprotective effects of DHA in AD.  In vivo studies 
have demonstrated the efficacy of DHA and its metabolites in reducing Aβ plaque 
burden, tau hyperphosphorylation and protecting against learning impairment in 
animal models [70-74]. In addition, the anti-inflammatory effect of DHA in reducing 
the release of inflammatory cytokines has also been demonstrated by different studies 
[75-77]. However, some clinical studies have reported no effect of DHA on 
behavioural disturbances or cognitive functions in mild-to-moderate AD patients [78-
80]. Thus, to clear this controversy surrounding DHA, additional studies need to be 
conducted to gather strong scientific evidence to explain the neuroprotective effects 
of DHA and promote its use as AD therapeutics or prophylactics. 
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Conventional biochemical approaches have thus far been used to elucidate the 
mechanism of action of DHA and its metabolites in AD [81-84]. However, more 
robust platforms are needed to simultaneously monitor the changes in different 
cellular networks affected by DHA and advance our understanding regarding its 
mechanism of action.  The emerging new technique of metabonomics promises to 
contribute significantly to the achievement of this goal and is discussed in detail in 
the following section. 
 
Metabonomics platform: An overview 
Over the years, the ‘omics’ technology using genomics, proteomics and 
metabonomics platforms has gained rapid popularity for conducting high throughput 
identification and quantification of large groups of targets, namely genes, proteins 
and metabolites, respectively.  Although the use of this technology in 
neurodegenerative diseases is relatively premature, it is quickly gaining interest 
owing to the large data-processing capacity, sensitivity and robustness of the 
platform. Particularly for a multifactorial disease like AD, these platforms provide 
excellent opportunity to gather high-density biological information related to different 
physiological and pathological processes much efficiently. The use of this technology 
can also provide a solution to the development and availability of sensitive and 
reproducible experimental platforms for monitoring biomarkers and drug responses, 
for drug screening process and to evaluate the efficacy and mechanism of the tested 
agents in AD.  
 
Amongst the different ‘omics’ based approaches, metabonomics provides holistic 
understanding of the disease process by allowing simultaneous identification and 
quantification of metabolites at molecular level in response to pathophysiological 
stimuli, environmental factor and disease processes. Since metabolome is 
downstream of genomic, transcriptomic and proteomic fluctuations, it represents an 
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accurate biochemical profile of the organism in healthy and disease conditions [85]. 
Moreover, due to the similarity between rodent and human metabolism, the results 
from rodent metabonomics studies can be easily translated to clinical settings for 
accelerating drug screening and designing process [85]. Contrary to the conventional 
biochemical approaches studying few metabolites at a time, this platform provides 
quantitative data over a wide range of known and unknown metabolites in the tested 
biological matrix. This overall metabolite pattern allows for comprehensive 
understanding of the interactions between different metabolites and metabolic 
pathways and their relation to the disease processes or responses to therapeutic 
interventions. It also allows for early stage disease biomarker identification, 
monitoring disease progression and clinical response to therapies. 
 
Metabonomics profiling can either be targeted or global, focussing on small number 
of known metabolites or including the entire metabolome of the biological matrix 
being analyzed, respectively. While the global metabonomic analysis allows for 
understanding the pathophysiological disorder resulting from complex interactions 
between various contributing factors, targeted profiling allows focussing on the role 
of a particular set of metabolites and associated pathway in the disease process in 
greater depth.  The most commonly used analytical techniques for metabonomics 
studies are liquid chromatography, gas chromatography and capillary electrophoresis 
coupled to mass spectrometry (LC/MS, GC/MS and CE/MS, respectively), as well as 
nuclear magnetic resonance (NMR). Each technique has associated advantages and 
drawbacks, but they are used for analysing different metabolites as per polarity and 
molecular weight range. 
 
The use of metabonomics in AD has also been reported in many studies. Several 
research groups have used this tool for profiling metabolic changes associated with 
AD progression and diagnosis and for identifying disease biomarkers for 
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differentiating clinically developed AD from healthy controls [86-89]. Although this 
platform can be used to understand drug response, its use to understand the 
mechanism of action or pharmacodynamic response of dietary and therapeutic agents 
in AD is relatively unexplored. We thus attempt to address this in this thesis by using 
the metabonomics platform for elucidating the mechanism of neuroprotective actions 
of docosahexaenoic acid in an AD cell model (Chapter 4 and 5).   
 
1.5 Challenges and limitations of the current therapeutic approaches 
The extent of investment by various pharmaceutical companies and research institutes 
in AD drug development pipeline is quite considerable.  However, to date there is no 
disease-modifying treatment available and the currently used drugs provide only 
symptomatic relief from secondary behavioural symptoms such as restlessness, 
agitation and depression. Despite the extensive ongoing research for developing novel 
disease-modifying agents, there has been no significant breakthrough in this area 
since the approval of memantine in 2002. Finding a single cure for AD may not be 
possible given the limited knowledge regarding the exact pathophysiology and the 
complexity of the disease. The results of the clinical developments of these novel 
agents have largely been a mix of promise and disappointment, for which several 
possibilities can be held accountable for.   
 
The first and the most prominent reason is the development of uni-target agents. AD 
being a multi-factorial disease, targeting a single causative agent at one time is not 
sufficient in producing an effective outcome. Ever since the initial understanding of 
AD pathology, all disease-modifying therapeutic strategies have been aimed at 
targeting Aβ or NFTs by means of reducing their production or increasing their 
clearance or both. However, the failure of these agents in the clinical trials has raised 
questions on the rationale for choosing Aβ or NFTs as the drug targets. With an 
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expansion in the understanding of the disease pathology, several approaches are now 
being tested by targeting other pathological contributors of the disease pathway.  
 
Secondly, there is a serious shortage of relevant animal models for AD studies.  Most 
of the animals used in AD studies are designed to model the disease pathway. The 
success of a novel agent in these animals only predicts that the agent can successfully 
interfere with the target pathway but gives no indication of its efficacy in treating the 
disease. This misinterpretation from animal models is mainly responsible for the 
failure of the agents that are successful candidates in pre-clinical screening but 
ineffective in showing any therapeutic benefits in clinical trials.   
 
Thirdly, there is an urgent need to identify suitable disease biomarkers and 
experimental tools that can help in identifying the disease at a very early stage and 
predict the outcome of the agent being tested. Lack of early stage disease biomarkers 
and experimental platforms makes the early identification of the disease very 
difficult, resulting in the clinical trials being conducted in patient cohorts that have 
already developed the disease. Not administering the drug at the right time may be 
one of the key contributors for the failure of these tested agents. In addition, 
optimization of drug dosage and treatment duration is required to assure a fair test of 
drug efficacy. Most of the randomized clinical trials are designed for duration of 18 
months, but this treatment duration may be very short for detecting a disease-
modifying effect.  
 
Lastly, the failure of several multicenter clinical trials [33] could also be due to 
improper design, random and systematic measurement errors, as well as due to 
monitoring, analysis and interpretation errors. More robust strategies and protocols 




1.6 Summary and concluding remarks  
As seen from this chapter, various hypotheses have been proposed to explain the 
molecular mechanisms leading to the widespread neurodegeneration observed in AD, 
yet, no conclusive details are available for either of them. Moreover, failures of uni-
targeted strategies in yielding any successful clinical outcome have further 
complicated our understanding of the disease pathophysiology. This fragmented 
knowledge has greatly impacted the availability of suitable cellular and animal 
models and retarded the development of useful diagnostic and therapeutic modalities. 
Utilization of alternative multi-targeted approaches and experimental tools will thus 
provide a means for potentiating the drug development process and therapeutic 





CHAPTER 2:  HYPOTHESIS AND AIMS 
 
Given the complexity of AD, the old hypothesis “one disease, one target, one drug” 
no longer stands valid and the current drug development methods need to be re-
evaluated. Multi-pronged approaches focussing on the interaction between the 
different pathological pathways in AD should be considered instead of single drug 
targets. Based on this emerging trend, the overall goal of this study is to identify 
novel modulators and targets for AD therapy with the aim of developing novel 
strategies to prevent disease progression or for use as prophylactics.  
 
In the first part of this thesis we hypothesized that enhanced neuroprotection may be 
provided by augmenting the therapeutic effects of GSK-3β inhibition by 
simultaneously inhibiting the dihydrofolate reductase (DHFR) enzyme. Our 
hypothesis was based on several observations: Firstly, GSK-3β has emerged as a 
common causal mediator involved in the mechanisms of various cellular events 
culminating in AD [37,40]. GSK-3β’s pleiotropic involvement in AD pathology has 
made it an important link between the triage of plaque and tangle pathology, 
oxidative stress and inflammation and hence, one of the most attractive target for the 
therapeutic drug development in AD. However, the therapeutic efficacy of currently 
available GSK-3β inhibitors is greatly limited by their low potency and adverse side 
effects. Secondly, DHFR enzyme has been reported to be a novel modulator of 
Wnt/β-catenin/GSK-3β signaling pathway by Klinghoffer and group [90].  They 
showed that the combined inhibition of DHFR enzyme and GSK-3β increased the 
potency of GSK-3β specific inhibitors in upregulating β-catenin transcription and 
translation and reducing lipopolysaccharide-induced production of inflammatory 
cytokines in peripheral blood mononuclear cells. Since both GSK-3β and DHFR 
enzyme inhibitors have been reported to have anti-inflammatory properties, we were 
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interested in assessing the effect of this synergistic inhibition in modulating AD 
pathogenesis.  
 
To test our first hypothesis, we explored three specific aims: 
(1) Investigate the effect of simultaneous DHFR and GSK-3β inhibition in 
modulating Wnt/β-catenin signaling pathway.  
(2) Assess the effect of the dual enzyme inhibition in improving neuronal cell 
survival against hydrogen peroxide-induced cytotoxic insults.  
(3) Determine the role of dual DHFR and GSK-3β inhibition in reducing 
oxidative stress and inflammation. 
 
Besides Aβ plaques and NFTs, mitochondrial dysfunctions, hypometabolism of the 
neuronal cells and deregulations in cholesterol metabolism pathway have also been 
important hallmarks of AD pathology. Accumulation and deposition of APP and Aβ 
in the mitochondrial matrix of neuronal cells have been held responsible for inducing 
these changes in the energy homeostasis [17]. Based on this hypothesis, there has 
been a significant increase in the number of studies being conducted for 
understanding the contribution of diet, especially PUFA, in the management of AD. 
DHA is one such PUFA whose anti-inflammatory and neuroprotective effects have 
already been extensively investigated in AD [91-94]. Nevertheless, its effect on APP-
induced disturbances in the energy metabolism and the cholesterol metabolism 
pathway has not been studied. Thus, in the second half of the project we hypothesized 
that APP induces metabolic perturbations in the Chinese hamster ovary cells and 
DHA plays a role in mitigating these disturbances. In this part, we focussed on 
elucidating the mechanism of DHA in mitigating APP-induced perturbations in 
energy and cholesterol metabolism pathways by characterizing and comparing the 




To test our second hypothesis, we had two specific aims: 
(1) Elucidate the metabolic phenotypes (metabotypes) associated with DHA 
therapy via global metabonomic profiling of an AD cell model using gas 
chromatography time-of flight mass spectrometry (GC/TOFMS) 
(2) Perform targeted metabonomic profiling of cholesterol metabolism pathway 
in DHA treated cells using gas chromatography – single quadrupole mass 
spectrometry (GC/MS). 
 
The experiments performed to address the specific aims of the first hypothesis are 
included in Chapter 3 where we report the synergistic effect of concurrent DHFR and 
GSK-3β enzyme inhibition in regulating Wnt/β-catenin signaling, neuronal cell 
survival, hyperphosphorylated tau formation and release of inflammatory mediators. 
The two aims of the second hypothesis are discussed in Chapters 4 and 5. In Chapter 
4 we report the positive effect of DHA in mitigating APP induced metabolic 
perturbations in cells using global metabonomics profiling approach. In Chapter 5 we 
report the effect of DHA on the deregulated cholesterol metabolism pathway in an 
AD cell model. To our knowledge, no such work has been previously reported for its 
application in AD research and thus there lies the potential and scope for novel 
research. 
 
Achieving the above aims not only provided us with a deeper understanding of the 
cross-talk between the two enzyme pathways in AD, but also a better insight for 
developing potential strategies using DHFR inhibition to enhance the therapeutic use 
of GSK-3β inhibitors in AD. Moreover, by using metabonomics platform our study 
provided an understanding of the metabolic changes induced by APP trafficking in 
the mitochondrial matrix and the effect of DHA in mitigating these disturbances. This 
knowledge is useful for providing valuable insights towards conceptualizing effective 






CHAPTER 3: DIHYDROFOLATE REDUCTASE ENZYME INHIBITION 
SYNERGIZES WITH A GLYCOGEN SYNTHASE KINASE-3β INHIBITOR 




Multiple hypotheses have been proposed to explain the pathophysiology of AD, a 
complex disorder of multiple cellular and biochemical changes. Although the exact 
sequence of events in AD etiology is still under debate, GSK-3 has been proposed as 
a common mediator underlying the mechanisms of various cellular events leading to 
AD. Extensive research has been carried out to understand the involvement of GSK-3 
and its isoforms, α and β, in oxidative stress, neuronal cell loss, inflammation, NFT 
and Aβ formation in AD. GSK-3β’s link to plaque and tangle pathology was brought 
forward by studies which showed that familial AD-linked presenilin-1 proteins 
formed complexes with β-catenin and GSK-3β [95-97], resulting in GSK-3β 
overactivation and consequent reduction in nuclear β-catenin levels, abnormal 
processing of Aβ peptides and hyperphosphorylation of tau proteins [98-100].  
 
Besides its involvement in amyloid cascade and tau pathology, contribution of GSK-
3β in inflammation and oxidative stress mediated damages has been widely studied 
for some time now. By regulating the expression and activity of NF-κB, GSK-3β 
plays an important role in the release of various inflammatory cytokines and 
oxidative stress mediators, namely nitric oxide (NO) and ROS [101-103]. Moreover, 
aberrant activation of GSK-3β has been observed to induce apoptosis in neuronal 
cells [104]. This pleiotropic involvement of GSK-3β has made it an attractive target 
for therapeutic drug development in AD and inhibiting GSK-3β activity via 
pharmacological intervention has been reported to improve neuronal survival 
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[105,106], reduce NFT formation and release of various inflammatory mediators 
[107]. 
 
Despite the wide understanding of GSK-3’s role as an important regulator of the 
disease pathogenesis, no effective therapeutic outcomes have materialized from it. 
Lithium is the only GSK-3 inhibitor clinically approved for treating 
neurodegenerative diseases. However, lithium’s benefits are severely outweighed by 
its non-specificity, high toxicity and adverse effects. Given the limited pool of safe 
and effective GSK-3 inhibitors, there exists a pressing need for identifying additional 
pathway regulators for enhancing the efficacy of GSK-3 inhibitors. In line with this 
notion, several strategies have been proposed for modulating GSK-3 activity, such as 
phosphorylation and regulation by Wnt/β-catenin signaling pathway, phosphatidyl 
inositol-3 kinase (PI3K)-Akt pathway or insulin/insulin growth factor (IGF)-1 
pathway [108]. In addition to these, a novel interaction between folate metabolism 
and β-catenin/GSK-3 signal transduction pathway has been recently shown by 
Klinghoffer and group to modulate GSK-3 activity [109]. In this study, we were 
interested in evaluating the possible application of DHFR inhibition in enhancing the 
potency of GSK-3β specific inhibitor for AD therapeutics. Using SH-SY5Y 
neuroblastoma cells and RAW264.7 mouse macrophage cells we demonstrated the 
efficiency of this approach in reducing hyperphosphorylation of tau protein and 
improving neuronal cell survival against cytotoxic insults in addition to an 
improvement in β-catenin transcription and anti-inflammatory effects. We expect that 
the findings from this study may stimulate further exploration of DHFR inhibition as 
a potential strategy to improve the therapeutic use of GSK-3β inhibitors in AD 




3.2 Materials and Methods 
3.2.1 Materials  
6’-Bromoindirubin-3’-oxime (BIO), methotrexate (MTX), β-mercaptoethanol, 
Dulbecco’s Modified Eagle’s Medium (DMEM), lipopolysaccharide (LPS) (from 
Escherichia coli 0111:B4), Griess reagent and 3-(4, 5 dimethyl-thiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St Louis, 
MO, USA). Opti-MEM, Lipofectamine 2000 and 6-carboxy-2', 7'-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) were purchased from 
Invitrogen (Carlsbad, CA, USA). Fetal bovine serum (FBS) was obtained from 
Thermo Scientific Hyclone (Logan, UT, USA). Dimethyl sulfoxide (DMSO) was 
purchased from MP Biomedicals (Santa Ana, California, USA). The primary 
antibodies for β-catenin, β-actin and Axin-2 were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA, USA). Phospho-GSK-3β-ser9 and DHFR 
antibody were purchased from Cell Signaling Technology (Beverly, MA, USA) and 
Abcam (Cambridge, MA, USA), respectively. Anti-human AT 8 phospho-PHF-tau 
pSer202/Thr205 antibody was purchased from Pierce Antibodies (Rockford, IL, 
USA). Secondary antibodies, anti-mouse and anti-rabbit IgG horseradish peroxidases 
were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). 
TOPglow reporter used in the luciferase reporter gene assays was purchased from 
Upstate Biotechnology (Lake Placid, NY, USA). pRL-CMV vector used for the 
normalization of TOPglow readings was obtained from Promega (Madison, WI, 
USA). 
 
3.2.2 Cell culture  
SH-SY5Y human neuroblastoma cells were kindly provided by Associate Professor 
Chun Kong Victor Yu (Department of Pharmacy, National University of Singapore, 
Singapore). RAW264.7 mouse macrophage cells were a kind gift from Assistant 
Professor Haishu Lin (Department of Pharmacy, National University of Singapore, 
24 
 
Singapore). Both the cells were cultured and maintained in DMEM medium 
supplemented with 10–15% FBS, 10 U/mL penicillin G and 100 µg/mL streptomycin, 
in a humidified atmosphere at 37°C containing 5% CO2. 
 
3.2.3 siRNA Transfection 
DHFR siRNA and universal scrambled negative control siRNA were purchased from 
OriGene Technologies (Rockville, MD, USA). The sequences of DHFR siRNA are as 
follows:  
• sequence A, 5’-AGCAAATAAAGTAGACATGGTCTGG-3’, DHFR 
positions 810 to 834  
• sequence B, 5’-GGTTTGTAGATAAATGTTGCCACCT-3’, DHFR 
positions 1448 to 1472  
• sequence C, 5’-AGCTGAGATGGAAGAATTAATTGAG-3’, DHFR 
positions 2677 to 2701.  
SH-SY5Y cells (1.2 × 106) were grown to 30-40% confluency in a 100 mm plate and 
were transfected with 10 nM and 20 nM DHFR siRNA and 10 nM of negative control 
siRNA using Lipofectamine 2000, according to the manufacturer’s instructions. Cells 
were grown for 48 h before harvesting and further analysis. All the three sequences 
were initially tested for their efficiency in knocking down DHFR gene in SH-SY5Y 
cells (Appendix A - Figure S1); however, due to the consistency of the knockdown 
observed, sequence B was used for all our studies.  
 
3.2.4 Collection of Wnt3a-conditioned media (Wnt3a-CM)  
To stimulate Wnt/β-catenin signaling, SH-SY5Y neuroblastoma cells are incubated 
with Wnt3a-CM, which causes the accumulation and stabilization of 
unphosphorylated β-catenin. To collect the CM, mouse Wnt3a-expressing cell line 
(L-Wnt3a cell) and the control non-transfected cell line (L-cell) were purchased from 
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American Type Culture Collection (Manassas, VA, USA) and cultured in DMEM 
containing 10% FBS and antibiotics. L-Wnt3a culture medium was supplemented 
with 0.4 mg/mL G418 to maintain selective pressure. Wnt3a-CM and conditioned 
medium from control L-cell (L-CM) was collected according to the manufacturer's 
instructions. Briefly, cells were seeded in 10 mL medium without G418 in 100mm 
culture dish and allowed to grow for 4 days. Medium was collected from each plate 
and replaced with 10 mL fresh medium for a further 3 days. This second batch of 
medium was then collected. First and second batches were combined, sterile filtered 
(0.2 µM) and stored at − 80 °C until further use. 
 
3.2.5 Cell proliferation assay  
The effect of BIO and MTX on the proliferation of SH-SY5Y cells was assessed 
using MTT assays. Briefly, SH-SY5Y cells were seeded into 96-well plates at a 
density of 1 × 104 cells per well and cultured for 24 h. Cells were then treated with 
BIO, MTX or DMSO (vehicle control) for 72 h. To evaluate the effect of DHFR and 
GSK-3β inhibitors in improving cell survival against hydrogen peroxide (H2O2) 
cytotoxicity SH-SY5Y cells were seeded into 96-well plates at a density of 2 × 104 
cells per well and cultured for 24 h. Cells were pre-treated with BIO, MTX or their 
combinations for 6 h followed by treatment with 30 µM H2O2 for another 16 h. At the 
end of the treatment durations, cell growth was analyzed by adding 40 µL of 5 
mg/mL MTT in 200 µL DMEM medium. Following an incubation period of 4 h, 
DMSO was added to lyse the cells and dissolve the purple formazan crystals. The 
absorbance of the formazan product was determined at λmax of 595 nm using a 
Tecan Spectra Fluor spectrophotometer (MTX Lab Systems Inc., Vienna, VA, USA). 
The IC50 values were obtained from the sigmoidal curve by plotting the percentage 
survival of cells against the concentration of the drugs using GraphPad Prism version 
5.00 for Windows, GraphPad Software (San Diego, CA, USA). The experiment was 
performed in triplicates and reported as mean ± S.E.M.  
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3.2.6 Luciferase reporter gene assay 
SH-SY5Y cells (1.0 × 105 per well) were grown to 80–90% confluency in 24-well 
plates and were transiently co-transfected with 1 µg TOPglow and 0.001 µg pRL-
CMV plasmids using Lipofectamine 2000, according to the manufacturer’s protocols. 
TOPglow firefly vector is used for evaluating β-catenin transcription activity whereas 
pRL-CMV renilla vector is used for normalizing the cell count. For some 
experiments, DHFR siRNA was transfected along with TOPglow and pRL-CMV 
plasmids to mediate DHFR inhibition instead of MTX. Twenty-four hours post-
transfection, cells were treated with BIO or MTX or their combination in Wnt3a CM 
for another 24 h. Following cell lysis, Luciferase assay was performed according to 
the kit instructions (Promega, Madison, WI, USA) and the luminescence output was 
determined using Infinite® 200Pro spectrophotometer (Tecan, Crailsheim, Germany). 
Results were expressed as mean ± S.E.M of normalized ratios of firefly and renilla 
luciferase activities for each triplicate sets. Reporter activities in BIO-, MTX-, 
siRNA- or combination-treated cells were expressed as percentage of control 
samples.  
 
3.2.7 Western blot analysis  
Cells were harvested and lysed in lysis buffer containing 1% Triton with protease 
inhibitor (Roche, Mannheim, Germany). Collected cell lysates were centrifuged at 
13000g for 10 min at 4°C and the protein concentration was determined by Bradford 
protein assay (Sigma Chemical Co., St Louis, MO, USA). 30 µg of protein samples 
were then electrophoresed on 10-15% polyacrylamide gel prepared using 30% 
acrylamide-bisacrylamide (BioRad, Hercules, CA, USA). The separated proteins 
were subsequently blotted onto nitrocellulose membranes (BioRad, Hercules, CA, 
USA) and blocked overnight at room temperature in tris-buffered saline containing 
0.1% (v/v) Tween 20 and 5% (w/v) fat-free dry milk, followed by incubation with the 
respective primary and secondary antibodies. Membranes were developed using West 
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Femto or West Pico luminal/enhancer solution (Pierce, Rockford, IL, USA) and 
stable peroxide solution (Pierce, Rockford, IL, USA) and the exposed X-ray films 
(ThermoFisher Scientific, Waltham, MA, USA) were processed using X-ray 
developing machine (Konica Minolta, Tokyo, Japan). Bands were quantified using 
ImageJ software (National Institutes of Health, MA, USA) normalized to β-actin 
loading control, before bands in treatment group were expressed relative to control 
(set as 100%). The experiment was performed at least in triplicates. The blots shown 
are representative of the triplicate runs. 
   
3.2.8 Measurement of NO production 
Decrease in generation of NO in LPS-stimulated RAW264.7 cells was determined by 
indirectly measuring the concentration of its stable metabolite, nitrite, using Griess 
assay. Cells were seeded at a density of 2 × 105 per 500 µL in 24-well plates. Twenty-
four hours post seeding, the cells were treated with BIO, MTX or their combinations 
in a serum free medium for a period of 6 h followed by treatment with 500 ng/mL 
LPS. At the end of 20 h treatment duration, 100 µL of cell-free supernatant was 
mixed with equal volume of Griess reagent in a 96-well plate and incubated at room 
temperature for 10 min in dark. The nitrite concentration was determined by 
measuring the absorbance at 540 nm using Infinite® 200Pro spectrophotometer 
(Tecan, Crailsheim, Germany) and quantifying it with sodium nitrite standard curve. 
Results were reported as percentage of LPS-treated samples. The experiment was 
performed in triplicates and reported as mean ± S.E.M. 
 
3.2.9 Measurement of intracellular ROS 
Intracellular ROS levels were measured using the fluorescent probe, carboxy-
H2DCFDA. This probe after crossing the plasma membrane is deacetylated to H2DCF 
and oxidized to the fluorescent product, DCF, by ROS. RAW264.7 cells were seeded 
at a density of 2 × 105 per 500 µL in 24-well plates. Twenty-four hours post seeding, 
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the cells were treated with BIO, MTX or their combinations in a serum free medium 
for a period of 6 h followed by addition of 500 ng/mL LPS. At the end of 24 h 
treatment duration, the cells were washed twice with PBS and scraped using a cell 
scraper in 400 µL of PBS. 200 µL of this cell suspension was then incubated with 10 
µM of carboxy-H2DCFDA for 30 min at 37°C in a 96-well opaque plate. 
Fluorescence intensity was measured using Infinite® 200Pro spectrophotometer 
(Tecan, Crailsheim, Germany) with excitation at 480 nm and emission at 538 nm. 
Results were reported as percentage of LPS-treated samples. The experiment was 
performed in triplicates and reported as mean ± S.E.M. 
 
3.2.10 Tumour necrosis factor-α ELISA Immunoassay 
The effect of dual enzyme inhibition on the release of tumour necrosis factor-α (TNF-
α) from LPS-stimulated RAW264.7 cells was evaluated using TNF-α sandwich 
ELISA immunoassays. RAW264.7 cells were seeded at a density of 2 × 105 per 500 
µL in 24-well plates for 24 h. Attached cells were then treated with BIO, MTX or 
their combinations in a serum free medium for 1 h followed by addition of 500 ng/mL 
LPS for another hour. At the end of 2 h treatment duration, cell-free culture medium 
was collected and analyzed for TNF-α release using the BD OptEIA™ ELISA kit 
(BD Biosciences, NJ, USA) following the manufacturer’s instructions. The 
experiment was performed in triplicates and reported as mean ± S.E.M. 
 
3.2.11 Statistical Analysis 
Statistical significance for treatment groups were analysed using one-way ANOVA 
with Bonferroni multiple comparisons (SPSS, Chicago, IL, USA). The difference 
between values for the treatments was considered to be statistically significant at 




3.3 Results  
3.3.1 Effect of MTX and BIO on SH-SY5Y cell viability 
MTT assay was carried out to assess the toxicity of BIO and MTX on SH-SY5Y cell 
viability and to identify their working concentrations for further studies. The IC50 
value for BIO after 72 h treatment in SH-SY5Y cells was calculated to be 0.26 ± 0.05 
µM. However, the IC50 value for MTX could not be calculated as SH-SY5Y cells 
showed resistance to MTX treatment, with cell death of only about 60% at the highest 
concentration used (Figure 3.1). The maximum concentration of BIO and MTX was 








Figure 3.1: Effect of BIO and MTX on SH-SY5Y cell viability. SH-SY5Y cells were 
treated with different concentrations of (a) BIO and (b) MTX for 72 h. Cell viability was 
evaluated by MTT assays. Data is presented as mean IC50 ± S.E.M relative to DMSO (vehicle 
control) from three independent experiments repeated in triplicate.  
 
3.3.2 DHFR inhibition by methotrexate enhances GSK-3β inhibitor activity by 
increasing β-catenin accumulation 
GSK-3β inhibitors have been shown to upregulate Wnt/β-catenin signaling in SH-
SY5Y neuroblastoma cells by relieving the negative regulation on cellular β-catenin 
degradation and downstream promoter activities [110,111]. In order to investigate the 
synergistic effect of DHFR and GSK-3β inhibition on the transcriptional activity of 
the Wnt/β-catenin signaling pathway, dual luciferase assays were conducted using 
TOPglow plasmid containing four copies of TCF binding sites for β-catenin protein. 
Western blot analyses were also carried out in SH-SY5Y cells to assess the 
translational activity of the pathway and β-catenin protein accumulation. 
 
As seen from the results of dual luciferase assay in Figure 3.2(a), co-treatment with 
BIO and anti-folate drug MTX significantly increased β-catenin/TCF transcriptional 
activity in SH-SY5Y cells as compared to using these agents alone. Statistical 
significance was observed for all the co-treatment groups compared to control, with 
different combinations of MTX (1 µM and 10 µM) and BIO (0.05 µM and 0.1 µM) 
causing an increase in reporter activity by ~36% to 98%. Since activation of β-
catenin/TCF signaling results from nuclear accumulation of β-catenin, we also 
assessed the effect of dual enzyme inhibition on β-catenin protein accumulation by 
using western blot analysis. As shown in Figure 3.2(c) and (d), in parallel with dual 
luciferase assay results, DHFR inhibition synergized with GSK-3β inhibition in 
enhancing β-catenin protein level in SH-SY5Y cells in a dose-dependent manner. 
This effect was however restricted to lower drug concentrations in both luciferase and 
western blot analyses, as at higher concentration combinations (0.1 µM BIO and 10 
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µM MTX) a decrease in the reporter activity was observed due to cell death (as seen 
from Renilla luciferase activity as shown in Figure 3.2(b). Nevertheless, the increase 
in β-catenin transcription and translocation activities was still significantly higher 
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Figure 3.2: DHFR inhibition by methotrexate enhances GSK-3β inhibitor activity by 
increasing β-catenin accumulation. (a) SH-SY5Y cells were co-transfected with TOPglow 
and pRL-CMV control vector and treated with different combinations of BIO and MTX. Data 
is presented as mean ± S.E.M of normalized ratios of firefly luciferase and renilla luciferase 
measurements from three independent experiments. Reporter activity in compound-treated 
cells was expressed as the percentage of DMSO-treated samples. */#p< 0.05, **/##p< 0.01 and 
***/###p<0.001, *compared to DMSO and #compared to BIO 0.1 µM; (b) Renilla luciferase 
activity in SH-SY5Y cells treated with BIO, MTX or their combination, expressed as 
percentage of control cells. *p< 0.05 and ***p<0.001 compared to control; (c) SH-SY5Y cells 
were treated with increasing concentrations of MTX in the presence of BIO and the collected 
cell lysates were subjected to western blot analysis. The blots shown are representative of 
three different experiments; (d) Cellular β-catenin protein expression quantified from the 
western blot results, expressed as percentage of control samples. **/##p< 0.01 and 




3.3.3 Silencing of DHFR enhances the effect of BIO-mediated increase in 
levels of GSK-3β-Serine9 phosphorylation, β-catenin protein and downstream 
marker, Axin-2 
Apart from using direct DHFR enzyme inhibitor, MTX, we also tested our hypothesis 
by knocking down DHFR gene using siRNA.  Results obtained were similar to that 
with MTX mediated DHFR inhibition. Compared to control, DHFR siRNA alone at 
10 nM and 20 nM concentrations increased the luciferase reporter activity by ~109% 
and ~144%, respectively, and when added in combination, reporter activity increased 
significantly in a dose-dependent manner with BIO (Figure 3.3(a)). Subsequent 
western blot analysis also showed an increase in the cellular accumulation of β-
catenin protein and Axin-2, a downstream Wnt target gene critical for cell 
proliferation (Figure 3.3(b) and (c)). As β-catenin protein accumulation is tightly 
regulated by GSK-3β activity, we next assessed the effect of increase in β-catenin 
accumulation on the phosphorylation of GSK-3β at Serine 9 position which results in 
inhibition of GSK-3β activity. As shown in Figure 3.3(b) and (c), treatment with BIO 
resulted in only modest increase in the levels of pGSK-3β-Ser9, whereas concurrent 
treatment with DHFR siRNA significantly augmented this accumulation. Taken 
together, our results show that DHFR enzyme inhibition synergizes with GSK-3β 
inhibition in upregulating the aberrantly inactivated Wnt/β-catenin/Tcf signaling 


























Figure 3.3: siRNA mediated DHFR inhibition enhances the potency of GSK-3β 
inhibitory effects. (a) SH-SY5Y cells were co-transfected with TOPglow and pRL-CMV 
control vector along with either negative control (10 nM) or DHFR siRNA sequence B (10 
nM and 20 nM) and treated with different concentrations of BIO. Data is presented as mean ± 
S.E.M of normalized ratios of firefly luciferase and renilla luciferase measurements from three 
independent experiments. Reporter activity in compound-treated cells expressed as percentage 
of DMSO-treated samples. */#p< 0.05, **/##p< 0.01 and ***/###p<0.001, *compared to DMSO and 
#compared to BIO 0.1 µM; (b) SH-SY5Y cells were treated similarly as mentioned above and 
cell lysates were subjected to western blot analysis. The blots shown are representative of 
three different experiments; (c) Cellular β-catenin, pGSK-3β-Ser9 and Axin-2 protein 
expression quantified from the western blot results, expressed as percentage of control 
samples. */#/$p< 0.05, **/##/$$p< 0.01 and ***/###/$$$p<0.001, *for β-catenin, #for pGSK-3β-Ser9 
and $for Axin-2, compared to respective controls. 
 
3.3.4 DHFR inhibition synergizes with GSK-3β inhibition in reducing tau 
phosphorylation 
GSK-3β is one of the protein kinases involved in the phosphorylation of tau protein 
[112]. Inhibition of GSK-3β through various small molecule inhibitors has been 
shown to reduce tau hyperphosphorylation and subsequent NFT formation in vitro 
and in vivo [113,114]. To assess whether DHFR inhibition enhanced this effect of 
GSK-3β inhibition, we treated SH-SY5Y cells concurrently with DHFR siRNA and 
BIO and subjected the collected cell lysates to immunoblotting with phospho-tau 
specific AT8 antibody directed against tau phosphorylation at Ser202/Thr205 
residues. As shown in Figure 3.4(a), GSK-3β inhibition alone resulted in a modest 
decrease in the levels of phospho-tau protein as compared to control; however, the 
combination of DHFR and GSK-3β inhibitor significantly increased this magnitude 
of reduction. The remaining level of tau phosphorylation observed was around 37.0 ± 
3.6% and 28.0 ± 2.7% in cells treated with a combination of 20 nM DHFR siRNA 
and BIO at 0.05 µM and 0.1 µM, respectively, against 76.4 ± 3.1% and 63.7 ± 5.7% 
reduction in cells treated with BIO 0.05 µM and 0.1 µM alone, when compared to 
control (Figure 3.4(b)). Treatment with DHFR siRNA alone also resulted in a 
decrease in phospho-tau protein levels (around 52.3 ± 3.9%). This observation can be 
attributed to an increase in pGSK-3β-Ser9 activity with DHFR siRNA, as shown in 
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Figure 3.4: DHFR inhibition synergizes with GSK-3β inhibition in reducing tau 
phosphorylation. (a) SH-SY5Y cells were transfected with either negative control (10 nM) or 
DHFR siRNA sequence B (20 nM) and treated with different concentrations of BIO. Cell 
lysates were collected 24 h post-treatment and subjected to western blot analysis. The blots 
shown are representative of three different experiments; (b) Cellular p-tau protein expression 
quantified from the western blot results, expressed as percentage of DMSO-treated samples. 
***p<0.001. 
 
3.3.5 Methotrexate enhances anti-oxidative and anti-inflammatory effects of 
GSK-3β inhibition  
Sustained production of NO has been shown to exert pro-inflammatory and oxidative 
stress mediated damages in a number of neuronal and inflammatory diseases [115]. 
Both GSK-3β and DHFR inhibitors have been reported to modulate NO generation, 
with MTX reported to inhibit the synthesis of tetrahydrobiopterin, an important 
cofactor essential for NO synthesis [116] and GSK-3β inhibitor reported to reduce 
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NO release from LPS-stimulated microglia [107]. Since both DHFR and GSK-3β 
inhibitors are known to exhibit anti-inflammatory effects and our data showed that 
DHFR inhibition enhances the potency of GSK-3β inhibition, we tested whether the 
combined usage of these two agents had any synergistic effect in enhancing anti-
oxidative and anti-inflammatory effect of GSK-3β inhibition. 
 
We pre-treated RAW264.7 mouse macrophage cells with BIO, MTX or their 
combination for a period of 6 h followed by stimulation with 500 ng/mL LPS. 
Release of NO was assessed by Griess assay and that of ROS by carboxy-H2DCFDA. 
As shown in Figure 3.5(a), MTX significantly reduced NO release from stimulated 
RAW264.7 cells as compared to LPS treatment alone; however, the extent of 
reduction was much higher with the combined usage of both the drugs. Contrary to 
the available reports, we did not find any significant decrease in NO levels with BIO 
treatment. This may possibly be due to the very low concentration of the drug used in 
our study (0.1 µM) as compared to that used by the other groups (~10 µM) [117]. On 
the other hand, statistical significance was observed for reduction in ROS generation 
for all the treatment groups, with production of ROS being severely blunted in cells 
pre-treated with the drug combination (27.3 ± 6.4%) as compared to those cells pre-
treated with either of the agents alone (48.7 ± 10.5% in MTX and 54.7 ± 2.9% in 
BIO) (Figure 3.5(b)).  
 
Besides its effect on NO and ROS production, the synergistic effects of concurrent 
DHFR and GSK-3β inhibition was also noted on the release of inflammatory 
cytokine, TNF-α from LPS-stimulated RAW264.7 macrophage cells using ELISA. 
As shown in Figure 3.5(c), compared to BIO or MTX alone, combined use of these 
two agents showed a significant decrease in TNF-α release from LPS-stimulated 
cells. This effect was not so prominent at 0.1 µM BIO concentration, nevertheless, a 
more prominent decrease was observed at 1 µM BIO concentration, which validated 
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our hypothesis that simultaneous DHFR inhibition enhanced the potency of GSK-3β 
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Figure 3.5: DHFR inhibition enhances anti-oxidative and anti-inflammatory effects of 
GSK-3β inhibition. RAW264.7 macrophage cells were pre-treated with different 
concentrations of BIO and MTX for 6 h followed by 500 ng/mL LPS treatment. (a) 100 µL of 
cell free supernatant was collected at the end of 20 h treatment duration and mixed with equal 
volume of Griess reagent. The release of NO was checked by measuring the absorbance at 540 
nm; (b) 24 h post-treatment cells were washed twice with PBS and treated with carboxy-
H2DCFDA. Level of intracellular ROS was measured by recording the fluorescence intensity 
at excitation at 480 nm and emission at 538 nm; (c) For the measurement of TNF-α release, 
RAW264.7 cells were pre-treated with BIO, MTX or their combinations for 1 h followed by 
treatment with 500 ng/mL LPS for another hour. The cell free supernatant was analysed by 
TNF-α ELISA kit. Data is presented as mean ± S.E.M relative to LPS treatment from three 
independent experiments. **p< 0.01 and ***p<0.001 compared to LPS treated samples.  
 
3.3.6 Dual enzyme inhibition improves neuronal cell survival by providing 
protection against hydrogen peroxide insults 
The ability of H2O2 to mediate oxidative stress and neurotoxicity in AD has been 
studied for a while. It is believed that H2O2 generation is enhanced by the initially 
formed Aβ [118], which in turn enhances ROS production and associated oxidative 
stress. These generated free radicals cause lipid peroxidation of the cellular 
membranes eventually resulting in neuronal cell loss. In order to assess whether the 
dual enzyme inhibition improved cell survival against H2O2 insults, we pre-treated 
SH-SY5Y cells with combination of BIO and MTX and then challenged them with 30 
µM H2O2. Cell viability was assessed using MTT analysis. As shown in Figure 3.6, 
when compared to H2O2 treated cells alone (41.8 ± 2.0% viability), both MTX and 
BIO helped in improving the cell viability to 60.4 ± 2.4% and 65.9 ± 0.9%, 
respectively, with the effect being more prominent in the cells pre-treated with their 
combination (74.9 ± 2.9%) . This improvement in cell viability may partly be 
attributed to the increase in the levels of β-catenin by the dual enzyme inhibition or to 
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Figure 3.6: Dual enzyme inhibition improves cell survival against H2O2-induced 
cytotoxicity. SH-SY5Y cells were pre-treated with BIO, MTX or their combinations for 6 h 
followed by treatment with 30 µM H2O2 for 16 h. Cell viability was measured using MTT 
assay. Data is presented as mean + S.E.M relative to DMSO (vehicle control) from three 
independent experiments repeated in triplicate. ***p< 0.001 compared to H2O2 treated samples.  
 
3.4 Discussion 
Over the years, the old assumption of Aβ being the precursor for the disease 
pathology is being increasingly refuted and amyloid accumulation is now being 
considered as a host response to the cellular injury caused by inflammation, oxidative 
stress and other cytotoxic events. Even NFTs are being recognized as an independent 
neuron-damaging agent rather than being a downstream consequence of Aβ-toxicity. 
Considering the complexity of the disease and the rise in the socio-economic burden 
with increasing incidences of AD, simultaneous targeting of multiple factors appears 
as a plausible approach for delaying the progression of injury and neurodegeneration 
in AD. 
 
The use of GSK-3β inhibitors and anti-inflammatory drugs have been proposed and 
studied for their therapeutic effects in AD cellular and animal models, however, this 
study was the first to show the combined use of DHFR and GSK-3β inhibitors in 
improving neuronal survival and reducing tau phosphorylation and oxidative stress. 
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Besides increasing the transcriptional and translational activities of β-catenin protein 
and Axin-2, pre-treatment with the dual enzyme inhibitors improved cell survival by 
providing protection against H2O2 induced cytotoxic insults. The decrease in ROS 
and NO generation and TNF-α release was even more pronounced with simultaneous 
inhibition of both the enzymes than inhibiting GSK-3β alone. The enhancement in the 
anti-inflammatory effect of these individual drugs upon combination was evident as 
both GSK-3β and DHFR inhibitors have been known to reduce inflammation by 
down-regulating NO production and the activation of NF-κB pathway and inhibiting 
the binding of inflammatory cytokines to their receptors.  
 
Although we have demonstrated the end benefits of using DHFR and GSK-3β 
inhibitors for AD therapeutics, the mechanism of interaction between GSK-3β/β-
catenin signaling and DHFR pathway seems complex and remains to be investigated. 
The preliminary experiments done by Klinghoffer and group to find answers for the 
same question revealed PI3K as a possible link [109]. Another plausible explanation 
for the observed synergy can be the interaction of both the enzymes and their 
inhibitors with the insulin pathway, upstream of the PI3K pathway. Inhibition of 
GSK-3β has been shown to improve insulin action, glucose metabolism and glucose 
tolerance in animals and hence GSK-3β inhibitors have been proposed for the 
treatment of type-II Diabetes Mellitus [119-122]. On the other hand, insulin has been 
reported to enhance the anti-tumoral potency of MTX [123-125] by modulating cell-
growth associated biochemical pathways, the exact mechanism of which is, however, 
yet not known. Connecting the dots between MTX, insulin and GSK-3β may provide 
a possible explanation for the observed synergy between GSK-3β and DHFR 
inhibition.  Nevertheless, proper investigation needs to be conducted in order to 
completely understand whether this observed synergy is a result of a cross-talk 
mechanism between the two pathways or a matter of chance occurrence. In addition 
to finding the mechanistic link, there also exists a challenge in optimizing the 
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combination concentration and the treatment duration of these drugs as both GSK-3β 
and DHFR enzymes have essential roles in other cellular processes, over and above 
their involvement in AD pathogenesis. The key is to develop effective combinations 
that will help in preventing neurotoxicity linked with cell death and inflammation 
without compromising the regular cellular processes of these enzymes.  
 
3.5 Conclusion 
Taken together, our results demonstrate that simultaneous DHFR inhibition enhanced 
the neuroprotective effects mediated by GSK-3β inhibition in modulating multiple 
pathophysiological pathways involved in the etiology of AD, namely cell survival, 
tau phosphorylation and inflammation. Deeper understanding of the interplay 
between the two enzyme pathways will provide better insights for developing 
potential strategies using DHFR inhibition to enhance the therapeutic use of GSK-3β 
inhibitors in AD. With the increase in the number of patients having overlapping 
pathological cascades and clinical features of different neurodegenerative diseases, 
this dual enzyme inhibition strategy may also be explored for developing therapeutic 





CHAPTER 4: GLOBAL METABOTYPING OF DOCOSAHEXAENOIC ACID 
– TREATED ALZHEIMER’S DISEASE CELL MODEL USING GAS 
CHROMATOGRAPHY/ TIME-OF-FLIGHT MASS SPECTROMETRY 
 
4.1 Introduction 
Impaired mitochondrial functions and hypometabolism of the neuronal cells have 
been characterized as neuropathological hallmarks of AD. Accumulation and 
deposition of APP and its cleaved fragment, Aβ, have been implicated in the 
inhibition of various mitochondrial enzymatic activities and for perpetration of 
oxidative stress-mediated damages [16,126-128]. APP localizes within the 
mitochondrial membranes and causes disruption of mitochondrial homeostasis and 
functioning of the ETC [16,27,129,130]. All these mitochondrial damages ultimately 
prevent the neuronal cells from functioning normally, leading to neuronal cell death.  
 
To counteract the neuronal damages mediated by these hypometabolic disturbances, 
alternative treatments in the form of nutritional interventions and dietary supplements 
has gained popularity for AD management.  In addition, recent evidence of the 
potential advantages of PUFAs, particularly DHA, in AD has lent further support to 
the contribution of diet in the management of this devastating disorder [131,132]. As 
mentioned in Chapter 1, several in vitro, in vivo and clinical studies have been 
conducted to assess the neuroprotective effects of DHA in AD. Moreover, lipidomics-
based approaches have identified neuroprotectin D1, resolvins and maresin as the 
potent metabolites of DHA having inflammation resolving and neuroprotective 
effects [67,133]. While the anti-inflammatory role of DHA has been investigated, its 
effect against APP-induced metabolic disturbances has not been studied. Thus, the 
aim of this part of the thesis was to elucidate the mechanism of action of DHA in 
mitigating APP-induced metabolic perturbations by characterizing and comparing the 
44 
 
metabolic phenotypes of DHA-treated and untreated wild type and APP-associated 
cells. 
 
Of the various approaches available to carry out the mechanistic studies, we chose the 
metabonomic platform as it gives an opportunity to capture the holistic profiling of 
various physiological processes undergoing in a cell at any moment. Moreover, this 
platform allows for the quantitative measurement of metabolites and their 
perturbations in different populations, offering insights into disease processes and 
pharmacological responses to therapeutic interventions and environmental stimuli. 
Amongst the different analytical tools used for conducting metabonomic studies, 
GC/TOFMS techniques have been well established and widely applied for the non-
targeted profiling of endogenous metabolites [134], rendering it an important 
component of the metabonomics toolbox. With its greatly enhanced chromatographic 
efficiency, improved sensitivity, resolution and analysis time, GC/TOFMS enables 
the high-throughput and high resolution separation and detection of broad range of 
metabolites in complex biological matrices. Coupled to the chemical library databases 
and chemometric data analysis, GC/TOFMS-based metabonomics facilitates efficient 
detection of the metabolic fluxes related to various pharmacological interventions. 
 
Thus, to address the aim of this study, a global metabonomics profiling of the 
medium and lysate of DHA- and vehicle-treated Chinese hamster ovary wild type 
(CHO-wt) cells and APP695-transfected CHO (CHO-APP695) cells was performed 
using the GC/TOFMS metabonomics. A brief summary of the adopted GC/TOFMS 
metabolite profiling method is shown in Figure 4.1. Our findings demonstrate for the 
first time that DHA plays a role in mitigating APP-induced impairment in energy 
metabolism and inflammation and sheds preliminary mechanistic insights on its 
neuroprotective effects. To our knowledge, no such reports regarding DHA 
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metabonomic profiling in AD cell model is yet available and there lies the novelty of 
our study. 
 
Figure 4.1: The experimental workflow for GC/TOFMS-based global metabolite 
profiling of DHA treated AD cell model. 
 
4.2 Materials and Methods   
4.2.1 Materials  
DMEM, succinic acid, glycine, citric acid, malic acid, mefenamic acid, silanization 
solution (5% dimethyl dichlorosilane in heptane), MTT and sodium sulfate were 
purchased from Sigma-Aldrich (St Louis, MO, USA). DHA and arachidonic acid 
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were obtained from Cayman Chemical Co. (Ann Arbor, MI, USA). Zeocin was 
purchased from Invitrogen (Carlsbad, CA, USA). FBS was obtained from Thermo 
Scientific Hyclone (Logan, UT, USA). N-Methyl-N-(trimethylsilyl) 
trifluoroacetamide (MSTFA) with 1% trimethylchlorosilane (TMCS) and 2% 
methoxamine hydrochloride in pyridine (MOX reagent) were purchased from Pierce 
(Rockford, IL, USA). Pyruvate dehydrogenase assay kit was purchased from Assay 
BioTech (Sunnyvale, CA, USA). Ultra-pure grade phosphate buffer saline (PBS) was 
obtained from 1st Base Private Limited (Singapore). DMSO, toluene and methanol 
were purchased from MP Biomedicals (Santa Ana, California, USA). Analytical 
grade reagents were used for all the work. 
 
4.2.2 Cell Culture  
CHO-wt and CHO-APP695 cells were kindly provided by Associate Professor Gavin 
S. Dawe (Department of Pharmacology, Yong Loo Lin School of Medicine, National 
University of Singapore) [135] and cultured and maintained in DMEM medium 
supplemented with 10% FBS, 10 U/mL penicillin G, 100 µg/mL streptomycin and 0.4 
mg/mL zeocin for CHO-APP695 cells, in humidified atmosphere at 37°C containing 
5% CO2.  
 
4.2.3 Cell Proliferation Assay 
The effect of DHA on CHO-wt and CHO-APP695 cells was assessed using MTT 
assay. Briefly, CHO-wt and CHO-APP695 cells were seeded into 96-well plates at a 
density of 1 × 104 cells per well and cultured for 24 h. Cells were then treated with 
DHA or DMSO (vehicle control) for 24 h. After treatment, cell growth was analysed 
by adding 40 µl of 5 mg/mL MTT in 200 µl DMEM medium. Following an 
incubation period of 4 h, DMSO was added to dissolve the purple formazan crystals. 
The absorbance of the product was determined at λmax of 595 nm using a Tecan 
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Spectra Fluor spectrophotometer (MTX Lab Systems Inc., Vienna, VA). The 
experiment was performed in triplicate. 
 
4.2.4 Western Blotting Analysis 
Western blotting was used to examine the expression of APP gene in CHO-wt and 
CHO-APP695 cells. Both the cell types were seeded at a density of 1 × 105 cells per 2 
mL of medium in 6-well plates. Twenty-four hours post-seeding the cells were 
harvested and lysed in lysis buffer containing 1% Triton with protease inhibitor 
(Roche, Mannheim, Germany). Protein concentration was determined by Bradford 
protein assay (Sigma Chemical Co., St Louis, MO, USA). 30 µg of protein lysates 
were then loaded in 10-15% polyacrylamide gel, prepared using 30% acrylamide-
bisacrylamide (BioRad, Hercules, CA, USA). The separated proteins were 
subsequently blotted onto nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) 
and blocked overnight at room temperature (24 ± 1°C) in tris-buffered saline 
containing 0.1% (v/v) Tween 20 and 5% (w/v) fat-free dry milk, followed by 
incubation with the anti-APP primary antibody (Merck KGaA, Darmstadt, Germany). 
Primary incubation was followed by incubation with secondary antibody after which 
the membranes were washed and incubated with the West Femto or West Pico 
luminal/enhancer solution and stable peroxide solution (Pierce, Rockford, IL, USA) 
before being exposed to an X-ray film (ThermoFisher Scientific, Waltham, MA, 
USA). The exposed films were subsequently processed using X-ray developing 
machine (Konica Minolta, Tokyo, Japan). All the experiments were performed at 
least in triplicates. 
 
4.2.5 Aβ40 ELISA Immunoassay  
Cells were seeded at a density of 1 × 105 cells per 2 mL of medium in 6-well plates. 
Twenty-four hours post-seeding the cells were treated with 25 µM DHA or vehicle-
control and the conditioned medium was collected from the cells after 24 and 48 h 
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treatment duration. The collected conditioned medium was centrifuged and the cell-
free supernatant was used for Aβ40 ELISA immunoassay using BetaMark™ x-40 
ELISA Kit (Covance Inc., NJ, USA) as per manufacturer’s instructions. 
 
4.2.6 Sample Preparation and Derivatization  
Cells were seeded at a density of 1 × 105 cells per 2 mL of medium in 6-well plates. 
Twenty-four hours post-seeding, 25 µM DHA was administered to the cells and 
DMSO (at a final concentration of 0.1% v/v) was used as the vehicle control. 
Treatment with both DHA and DMSO was terminated after 24 h by harvesting the 
culture medium and washing the cells twice with ice-cold PBS. The collected culture 
medium was centrifuged and the cell-free supernatant was stored immediately at -
80°C until further analysis. After quenching the metabolism with 1 mL ice-cold 
methanol, cells were collected and stored at -80°C until further sample preparation. 
Six independent biological replicates were examined for each treatment group. Prior 
to derivatization, all the samples were thawed at room temperature (24 ± 1°C). For 
culture medium, 200 µL of each sample was mixed with 150 µL of 100 µM 
mefenamic acid in water (internal standard) and 1 mL methanol and vortex-mixed at 
a high speed for 5 min. All the tubes were subsequently centrifuged at 10,000g for 10 
min at 4°C and 950 µL of supernatant from each sample was transferred into 15 mL 
silylated glass tubes. Likewise, for cell lysate, 300 µL of 100 µM mefenamic acid in 
water and 200 µL of methanol were added to the pooled cells in 1 mL cold methanol 
and cell disruption was performed with a ball mill for 5 min at 25 Hz using 4 mm 
stainless steel beads. The extracts were then placed on ice for 20 min, followed by 
centrifugation at 17,500g for 10 min at 4°C. 1.4 mL of each supernatant was 
transferred to silanized glass tubes. The collected supernatants of all the samples were 
then dried at 50°C under a gentle stream of nitrogen gas using the TurboVap LV 
(Caliper Life Science, Hopkinton, MA, USA), followed by an additional drying step 
after addition of 100 µL of anhydrous toluene (dried over anhydrous sodium sulfate) 
49 
 
to ensure complete removal of water. The dried extract were then subjected to 
methoximation using 50 µL of MOX reagent (2 h at 60°C), followed by trimethylsilyl 
(TMS) derivatization using 100 µL of MSTFA with 1% TMCS as catalyst (1 h at 
60°C). The formed TMS derivatives were cooled to room temperature (24 ± 1°C) and 
transferred to the autosampler vials for GC/TOFMS analysis. 
 
4.2.7 GC/TOFMS Conditions  
GC/TOFMS analysis was performed on an Agilent 7890A Gas Chromatography 
(Agilent Technologies, Santa Clara, CA, USA) coupled to a PEGASUS 4D Time-of-
Flight Mass Spectrometer (LECO Corporation, St. Joseph, MI, USA). The primary 
column used was a DB-1 GC column (Agilent Technologies) of internal diameter of 
250 µm, length of 23 m and film thickness of 0.25 µm. Helium was used as the carrier 
gas at a flow rate of 1 mL/min. The injection volume was 1 µL. A splitless injection 
was used for the cell media while a split ratio of 1:2 was used for the cell lysate. The 
optimized GC/MS front inlet and ion source temperatures were 250 and 200°C, 
respectively. The oven temperature was kept at 70°C for 20.0 min, increased to 
250°C at 8°C/min and finally to 300°C at 40°C/min where it remained for 6 min. The 
transfer line was maintained at 250°C. The MS was operated using an electron impact 
(EI) ionization source at -70 eV and a detector voltage of 1800 V. The MS data were 
acquired in scan mode over the range m/z 50–600 at a rate of 15 spectra/s. Peaks with 
signal-to-noise (S/N) ratio lower than 100 were rejected. Quality control (QC) 
samples were prepared by randomly pooling 40 µL from each of the six medium 
samples of the control group. Alkane series C8-C40 and fatty acid methyl esters 
(FAME) (C8 – C28) standards were analyzed with the same GC program for 
calculation of the retention index of the metabolites. LECO ChromaTOF software 
(version 4.21, LECO Corporation, St. Joseph, MI, USA) was used for chromatogram 
acquisition, peak deconvolution, analyte alignment and preliminary analyte 
identification by the National Institute of Standards and Technology (NIST) library 
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(Wiley registry, NJ, USA), Fiehn library and internal spectral libraries. Based on the 
library matching, peaks with similarity index of more than 60% were given putative 
metabolite identities.  
 
4.2.8 Multivariate Data Analysis and Metabolite Identification  
The peaks were normalized to the total integral area prior to chemometric and 
statistical data analysis. All processed data were mean centered and scaled to unit 
variance during chemometric data analysis. Principal component analysis (PCA) and 
partial least squares and discriminant analysis (PLS-DA) were employed to process 
the acquired and normalized data using SIMCA-P+ software (version 11, Umetrics, 
Umeå, Sweden). PCA score plots were used for observing the clustering trend among 
the samples as well as to detect and exclude outliers. After exclusion of outliers, 
medium and lysate samples were further subjected to PLS-DA for identifying models 
that differentiated groups or classes. The validity of the model was checked by 
performing 100 permutation tests. The criteria for model validity are as follows. First, 
all the Q2 values on the permuted data set must be lower than the Q2 value on the 
actual data set. Second, the regression line in validation plot (line joining the actual 
Q2 point to the centroid of the cluster of permuted Q2 values) must demonstrate a 
negative intercept on the y-axis. The validated models were subsequently utilized for 
identifying unique metabotypes associated with the DHA- and vehicle-treated groups. 
Variable importance in the projection (VIP) cutoff value was set as 1.00. Statistical 
comparison of discriminant metabolite levels between different groups was carried 
out using independent t-test with Welch’s correction; metabolites with a p-value of 
less than 0.05 being considered to be statistically significant. These putative marker 
metabolites were then cross-referenced against the Golm Metabolite Database (GMD) 
[136] and the Human Metabolome Database (HMDB) [137]. Identities of these 
metabolites were further ascertained by comparing their mass spectra and retention 
indices with that of commercially available reference standards Lastly, the Kyoto 
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Encyclopaedia of Genes and Genomes (KEGG) [138] database was used for the 
interpretation of the metabolic pathways of the identified marker metabolites. 
Difference in the levels of metabolite between the treatment group was assessed by 



















= , values >1 and <1 represented higher and lower 
metabolite levels observed in that treatment group, respectively. 
 
4.2.9 Pyruvate Dehydrogenase Enzyme Assay  
Both CHO-wt and CHO-APP695 cells were seeded at a density of 1.5 x 106 per 10 mL 
in a T75 flask followed by treatment with either 25 µM DHA or DMSO as vehicle 
control. The cells were harvested 24 h post treatment and lysed in lysis buffer 
containing 1% Triton with protease inhibitor (Roche, Mannheim, Germany). Each 
cell lysate mixture was centrifuged at 13000g for 10 min at 4°C and protein 
concentration of the soluble extract was determined by Bradford protein assay. An 
aliquot of the supernatant was diluted with the lysis buffer to achieve a protein 
concentration of 400 µg/mL for each sample. The assay was conducted as per the 
manufacturer’s instructions with the final enzyme activity being assessed by 
measuring the reduction of NAD+ to NADH at 340 nm using Infinite® 200Pro 
spectrophotometer (Tecan, Crailsheim, Germany). Pyruvate dehydrogenase (PDH) 
enzyme concentration (mU/mL) was determined from the regression equation of the 











Statistical analysis was done via ANOVA with Bonferroni's post-hoc analysis, with 
**p<0.01 and ***p<0.001 considered to be statistically significant. 
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4.3 Results  
4.3.1 Effect of DHA on viability of CHO-wt and CHO-APP695 cells 
The effect of DHA on CHO-wt and CHO-APP695 cell viability was evaluated using 
MTT assays to select a DHA concentration for conducting the experiments. Based on 
the survival curve obtained after 24 h treatment duration (Figure 4.2) 25 µM dose of 
DHA was selected for carrying out further analysis as it resulted in no significant 
toxicity and no less than 80% cell survival in both the cell types. 


























Figure 4.2: Concentration-dependent effect of DHA on CHO-wt and CHO-APP695 cell 
viability. MTT assay was carried out to assess the effect of DHA on the viability of both the 
cell types following 24 h treatment duration. The data as derived from three independent MTT 
experiments repeated in triplicate is presented as mean ± S.E.M relative to DMSO (vehicle 
control). 
 
4.3.2 Cell Model Validation and effect of DHA on Aβ40 release 
APP
 
are transmembrane glycoproteins that exist in three major isoforms, 770, 751 
and 695, of which the 695 fragment containing 695 amino acids is predominantly 
expressed in neuronal cells [139]. Various in vitro AD cell models have been 
developed overexpressing APP695 fragment for AD studies including CHO-APP695 
[140-144]. To validate our cell model, western blot analysis was performed and 
confirmed the overexpression of APP695 protein in CHO-APP695 cells compared to the 
parental CHO-wt cells (Figure 4.3a). Besides using western blot analysis, we also 
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validated our model using Aβ40 ELISA immunoassay. Cleavage of APP by β- and γ-
secretases yields numerous Aβ fragments, of which Aβ40 and Aβ42 are the most toxic. 
Among the two, Aβ40 has been found to be 10-fold higher in abundance than Aβ42 in 
patients with sporadic AD [145]. Our ELISA immunoassays showed that Aβ40 is 
released significantly only in the conditioned medium of CHO-APP695 cells, even 
after 48 h (Figure 4.3b). These results established the validity of our cell model for 
subsequent metabolomic analysis.  
 
Several research groups have reported the effect of DHA treatment in reducing the 
release of Aβ from its precursor, APP [146-148]. In order to evaluate the biological 
effects of DHA, we also undertook a similar experiment wherein we evaluated the 
effect of DHA on the release of Aβ40 from CHO-APP695 cells. As seen from Figure 
4.3b, release of Aβ40 was significantly higher at both 24 and 48 h time duration as 
compared to CHO-wt cells, with the release at 48 h time duration being 
comparatively higher than that at 24 h. DHA treatment at 25 µM concentration was 
able to decrease the release of Aβ40 from CHO-APP695 cells at both 24 and 48 h 
treatment durations by approximately 50%. In addition to the metabolomics data, this 
result helped in corroborating the effect of DHA in reducing APP mediated release of 
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Figure 4.3: Model validation for CHO-wt and CHO-APP695 cells and effect of DHA on 
Aβ40 release. (a) Western blot analysis of the cell lysates confirm APP695 plasmid 
overexpression in CHO-APP695 cells compared to CHO-wt; (b) Conditioned medium was 
collected from CHO-wt and CHO-APP695 cells with and without DHA treatment for Aβ40 
ELISA immunoassays
. 
There was negligible release of Aβ40 from CHO-wt cells as compared 
to CHO-APP695 cells at 24 and 48 h. A significant decrease was observed in the release of 
Aβ40 in CHO-APP695 cells after treatment with 25 µM DHA for 24 h and 48 h. #p < 0.001 as 
compared to CHO-wt vehicle treated cells, ϕp < 0.05 compared to CHO-APP695 24 h vehicle 
treatment and §p < 0.001 as compared to CHO-APP695 48 h vehicle treatment. Analysis was 
done via ANOVA with Bonferroni's post-hoc analysis. 
 
4.3.3 GC/TOFMS Metabolic Profiling 
Representative GC/TOFMS chromatogram of medium and lysate samples of DHA- 















Figure 4.4: Overlay of GC/TOFMS chromatograms. Representative GC/TOFMS 
chromatogram of DHA-treated and vehicle-treated, (a) CHO-wt and (b) CHO-APP695 cells - 
lysate (L) and medium (M) samples; (c) Representative chromatogram demonstrating 
discriminatory metabolites between vehicle-treated and DHA-treated CHO-wt cells and CHO-
APP695 cells. 
 
Based on the results obtained, two models were generated for our analysis:  
a) Model 1 
Model 1, a comparison between DHA- and vehicle-treated CHO-APP695 cells, was 
analogous to clinical trials comparing the effect of a test drug versus placebo in the 
diseased patients. As shown in Figure 4.5, unsupervised PCA scores plot revealed a 
clustering trend between the DHA-treated and vehicle-treated groups using both the 
lysate (R2X=0.634 and Q2(cum)=0.162) and the medium (R2X=0.556 and 
Q2(cum)=0.201) as the sample matrices. Subsequent supervised PLS-DA model was 
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optimized with 3 latent variables (LV) for both the medium (R2X=0.627, R2Y=0.999 
and Q2(cum)=0.909) and lysate (R2X=0.364, R2Y=0.992 and Q2(cum)=0.669) 
samples. Table 4.1 summarizes a list of discriminant marker metabolites in PLS-DA 
model. The levels of citric acid, succinic acid, malic acid, glycine, DHA, fructose and 
3-phosphoglycerate were found to be elevated with DHA treatment while that of 
arachidonic acid, cholesterol, zymosterol and fumaric acid were found to be 
significantly lowered in the samples.  
 
Figure 4.5: PLS-DA score plot and validation plots. DHA-treated versus vehicle-treated 
CHO-APP695 (a) lysate samples (2X=0.364; R2Y=0.992; Q2 (cum)=0.669; LV = 3) and (c) 
medium samples (R2X=0.627; R2Y=0.999; Q2 (cum)=0.909; LV=3); Validation plot of the 




Table 4.1: Discriminatory marker metabolites identified from medium and lysate samples of DHA-treated and vehicle-treated CHO-APP695 cells. 







Normalized peak area(x 10-4)c Fold ∆d Vehicle-treated DHA-treated 
Citric acid lysate TCA standard 1844.5 13.5 ± 3.2 29.6 ± 2.4* 2.19 
Malic acid lysate TCA standard 1501.6 21.6 ± 1.2 25.2 ± 1.7* 1.17 
Succinic acid lysate TCA standard 1305.9 1.7 ± 0.3 2.6 ± 0.3* 1.50 
DHA lysate Fatty acid standard 2552.3 3.8 ± 0.3 5.5 ± 0.7* 1.45 
Fructose lysate carbohydrate standard 1928.1 21.9 ± 2.6 31.5 ± 1.2* 1.44 
3-phosphoglycerate lysate carbohydrate standard 1825.4 0.7 ± 0.1 1.1 ± 0.1* 1.67 
Arachidonic acid lysate Fatty acid standard 2352.8 3.4 ± 0.4 2.7 ± 0.2* 0.79 
Zymosterol lysate Steroid NIST 3170.0 7.6 ± 0.9 6.5 ± 0.6* 0.86 
Cholesterol  lysate Steroid standard 3167.4 422.6 ± 51.5 315.4 ± 48.9* 0.75 
Fumaric acid lysate TCA standard 1346.4 10.4 ± 0.5 3.1 ± 0.7* 0.30 
Succinic acid medium TCA standard 1305.9 3.7 ± 0.1 4.1 ± 0.3* 1.11 
Citric acid medium TCA standard 1844.5 0.2 ± 0.1 0.4 ± 0.0* 1.91 
Glycine medium Amino acid standard 1316.1 102.1 ± 29.4 284.5 ± 47.6* 2.79 
a Metabolite identification using standard compound or NIST library search. 
b Kovats RI refers to Kovats retention index. 
c
 Normalized peak area values expressed as mean ± S.E.M. 
d
 Fold change (∆): CHO-APP695 (DHA-treated) / CHO-APP695 (vehicle-treated). 
* p<0.05 and ns not significant when calculated using the independent t-test with Welch’s correction for normalized peak area. 
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b) Model 2 
Model 2 was a comparison between DHA- and vehicle treated CHO-wt and CHO-
APP695 cells, which was surrogate for clinical trials comparing the effect of the test 
drug and placebo in diseased patients with age-matched healthy volunteers.  Similar 
to model 1 results, chemometric data analysis revealed a distinct clustering trend 
between CHO-wt and CHO-APP695 cells treated with DHA and vehicle control in 
both the lysate and medium samples (Figure 4.6 and 4.7).  
 
Figure 4.6: PLS-DA score plot and validation plot for lysate samples. (a) PLS-DA score 
plot of vehicle-treated CHO-wt and CHO-APP695 lysate samples (R2X=0.474; R2Y=0.985; Q2 
(cum)=0.808; LV=2); (b) Validation plot of the PLS-DA model obtained from 100 
permutation tests for vehicle-treated lysate samples; (c) PLS-DA score plot of DHA-treated 
CHO-wt and CHO-APP695 lysate samples (R2X=0.645; R2Y=0.993; Q2 (cum)=0.971; LV=2); 
(d) Validation plot of the PLS-DA model obtained from 100 permutation tests for DHA-
treated lysate samples. 
 
For lysate samples, unsupervised PCA scores plots showed differences between the 
two cell types in vehicle-treated (R2X=0.578 and Q2 (cum)=0.295) and DHA-treated 
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groups (R2X=0.655 and Q2 (cum)=0.432) and . A similar clustering was observed for 
medium samples in vehicle-treated (R2X=0.990 and Q2 (cum)=0.114) and DHA-
treated groups (R2X=0.681 and Q2 (cum)=0.459).  Subsequent supervised PLS-DA 
model uncovered a list of putative marker metabolites that were significantly different 
(p<0.05 for T-test with Welch’s correction) and characterized the metabotypes 
associated with DHA treatment effect. Here, PLS-DA model was optimized with 2 
latent variables (LV) for lysate samples: vehicle-treated (R2X=0.474, R2Y=0.985 and 
Q2 (cum)=0.808) and DHA-treated groups (R2X=0.645, R2Y=0.993 and Q2 
(cum)=0.971), whereas model for medium samples was optimized with 3 LV: 
vehicle-treated (R2X=0.679, R2Y=0.994 and Q2 (cum)=0.929) and DHA-treated 
groups (R2X=0.745, R2Y=0.992 and Q2 (cum)=0.885). All the PLS-DA models were 
found to be valid with no overfitting of data based on the criteria of the permutation 





Figure 4.7: PLS-DA score plot and validation plot for medium samples. (a) PLS-DA score 
plot of vehicle-treated CHO-wt and CHO-APP695 medium samples (R2X=0.679; R2Y=0.994; 
Q2 (cum)=0.929; LV=3); (b) Validation plot of the PLS-DA model obtained from 100 
permutation tests for vehicle-treated medium samples; (c) PLS-DA score plot of DHA-treated 
CHO-wt and CHO-APP695 medium samples (R2X=0.745; R2Y=0.992; Q2 (cum)=0.885; 
LV=3); (d) Validation plot of the PLS-DA model obtained from 100 permutation tests for 
DHA-treated medium samples. 
 
A list of discriminant identified marker metabolites that significantly differentiated 
DHA-treated and vehicle-treated groups in PLS-DA model 2 for both CHO-wt and 
CHO-APP695 cell types is summarized in Table 4.2. As shown, the levels of citric 
acid, malic acid and DHA were found to be elevated while that of arachidonic acid, 
cholesta-3, 5-diene and zymosterol were found to be significantly lowered in DHA 
treated lysate samples. Similarly, in medium samples, the levels of glycine, malic 
acid and succinic acid were found to be elevated in DHA-treated groups.  
 
Overall, from the results of both model 1 and 2 (Table 4.1 and 4.2) and Figure 4.2, 
we can see that even before sufficient release of Aβ40 in the culture medium (24 h 
versus 48 h), APP induced metabolic changes in CHO-APP695 cells compared to 
CHO-wt cells. The metabolic networks for these identified metabolites were 
correlated with specific metabolic pathways of TCA cycle (citric acid, succinic acid, 
fumaric acid and malic acid), cholesterol metabolism (zymosterol, cholesterol and 
cholesta-3, 5-diene), fatty acid biosynthesis (DHA and arachidonic acid), glucose 
metabolism (fructose and 3-phosphoglycerate) and amino acid metabolism (glycine). 
As temporal longitudinal metabolic flux measurements (fluxomics experiments) had 
not been performed in this study, neither the relationships between the lysate versus 
medium marker metabolites nor the rates of metabolic reactions in biological systems 
could be determined. Table 4.3 summarizes the findings about the marker 




Table 4.2: Discriminatory marker metabolites identified from medium and lysate samples of DHA-treated and vehicle-treated CHO-wt and CHO-
APP695 cells 















CHO-wt CHO-APP695 CHO-wt CHO-APP695 
Citric acid lysate TCA standard 1844.5 7.5 ± 0.9 8.4 ± 3.3* 1.12 16.6 ± 1.5 33.0 ± 2.4* 1.99 
Malic acid lysate TCA standard 1501.6 20.5 ± 1.5 21.6 ± 1.3ns 1.05 16.6 ± 0.9 25.3 ± 1.7* 1.52 
DHA lysate Fatty acid standard 2552.3 3.2 ± 1.4 2.5 ± 0.7* 0.79 3.5 ± 0.2 4.5 ± 0.3* 1.28 
Arachidonic acid lysate Fatty acid standard 2352.8 3.1 ± 0.3 3.5 ± 0.4* 1.17 3.2 ± 0.1 2.7 ± 0.3* 0.85 
Zymosterol lysate Steroid NIST 3170.0 4.3 ± 0.4 7.6 ± 0.9* 1.76 4.2 ± 0.3 6.6 ± 0.7* 1.59 
Cholesta-3,5-
diene lysate Steroid NIST 2885.6 3.0 ± 0.3 3.1 ± 0.4
 ns
 1.05 3.0 ± 0.4 1.5 ± 0.5* 0.52 
Succinic acid medium TCA standard 1305.9 3.2 ± 0.5 3.5 ± 0.1ns 1.09 3.4 ± 0.3 4.1 ± 0.3* 1.20 
Malic acid medium TCA standard 1501.6 1.3 ± 0.1 1.2 ± 0.3ns 0.92 1.4 ± 0.1 1.6 ± 0.1* 1.17 
Glycine medium Amino acid standard 1316.1 80.8 ± 20.9 102.1 ± 29.4ns 1.30 181.4 ± 58.3 284.6 ± 47.6* 1.56 
a Metabolite identification using standard compound or NIST library search. 
b  Kovats RI refers to Kovats retention index. 
c
 Normalized peak area values expressed as mean ± S.E.M. 
d
 Fold change (∆): CHO-APP695 (treatment) / CHO-wt (treatment). 
*
 p<0.05 and ns not significant when calculated using the independent t-test with Welch’s correction for normalized peak area of CHO-APP695 cells compared 
to CHO-wt cells for respective treatment groups. 
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Table 4.3: Metabolites, their associated metabolic pathways and biological relevance 
in AD 
Metabolitesa Metabolic pathwayb Biological relevance in AD 
Citric acid (↓) TCA cycle 
APP-induced metabolic 
perturbations resulting in 
deregulation of glucose 
metabolism, TCA cycle, 
hypometabolism and increased 
oxidative damages in neuronal 
cells 
Succinic acid (↓) TCA cycle 
Malic acid (↓) TCA cycle 
Fumaric acid (↑) TCA cycle 
Fructose (↓) Glucose metabolism 
3-phosphoglycerate (↓) Glucose metabolism 
Glycine (↓) 
Glycine, serine and 
threonine 
metabolism 
Required for synthesis of heme 
which is essential for functioning 
of electron transport chain 
Zymosterol (↑) Steroid biosynthesis Increased risk of formation and 
deposition of amyloid beta 
plaques from APP Cholesterol (↑) Steroid biosynthesis 
Cholesta-3,5-diene (↑) Steroid biosynthesis 
One of the toxic oxysterol 
product of cholesterol 
metabolism found in increased 
levels in AD brain 
Arachidonic acid (↑) Eicosanoid biosynthesis 
Generation of pro-inflammatory 
and inflammatory mediators in 
AD 
DHA (↓) Biosynthesis of 
omega-3 fatty acids 
Decreased levels observed in AD 
brain affecting vision, 
neuroprotection, successful 
aging, memory and inflammation 
resolving properties 
aMetabolites are grouped together on the basis of their biological relevance. (↑) elevated 
in AD and (↓) reduced in AD. 




4.3.4 Pyruvate Dehydrogenase Enzyme Assay 
PDH is a rate limiting enzyme connecting the glycolysis and TCA cycle and is found to 
be significantly decreased in AD patients. Similarly, as seen in Figure 4.8, PDH enzyme 
concentration (mU/mL) was observed to be significantly lower in vehicle treated CHO-
APP695 compared to CHO-wt cells (50.3 ± 5.9 vs. 80.5 ± 7.1, ***p< 0.001) in our study. 
This decrease in PDH enzyme activity in CHO-APP695 confirmed the involvement of 
APP in perturbing mitochondrial enzymatic activities and provided an additional 
validation for the use of these cells as surrogate models for the diseased and healthy 
patients. DHA treatment for 24 h increased the enzyme concentration in both CHO-wt 
(96.1 ± 2.2) and CHO-APP695 (72.1 ± 7.1) cells as compared to their respective vehicle 
controls. This increase in enzyme concentration in DHA-treated CHO-APP695 cells was 
statistically significant as compared to vehicle-treated CHO-APP695 cells (72.1 ± 7.1 vs. 
































Figure 4.8: DHA treatment increases pyruvate dehydrogenase enzyme concentration in 
CHO-wt and CHO-APP695 cells. Pyruvate dehydrogenase activity in CHO-wt and CHO-APP695 
cells treated with vehicle or 25 µM DHA. Values are means ± SEM from three independent 
experiments. **p < 0.01 and ***p < 0.001 as compared to CHO-APP695 vehicle treated. Analysis 





Mitochondrial dysfunctions and associated energy hypometabolism have been considered 
as one of the important factors contributing to the pathology of AD. Significant amount 
of work has been done by various research groups showing the deleterious effects of Aβ 
on the mitochondrial activity. However, it has been suggested recently that APP, the 
parent precursor to Aβ, is toxic and affects cellular metabolic activities. Trafficking of 
APP in the mitochondrial matrix has been reported to impair functions of various 
mitochondrial enzymes and leading to disturbances in energy metabolism [126,149]. 
Amongst the affected enzymes of TCA cycle, activity of α-ketoglutarate dehydrogenase, 
pyruvate dehydrogenase and isocitrate dehydrogenase have been reported to be markedly 
decreased in autopsied brains of AD patients while the activity of succinate 
dehydrogenase and malate dehydrogenase have been shown to be markedly increased 
[150]. These enzyme alterations result in a reduction of succinyl CoA via its rapid 
conversion to other metabolites that in turn reduces the production of heme, a porphyrin 
molecule necessary for maintaining the integrity of the ETC. This net decrease in the 
production of ATP molecules establishes a state of hypometabolism and oxidative stress 
in an AD brain.  
 
Based on the results of pre-clinical and clinical studies, the therapeutic effects of DHA 
and its isolated metabolites in mitigating Aβ- induced neurodegeneration, memory 
impairment and inflammation have been established [72,73,79,151-153]. DHA has also 
been shown to reduce the generation of Aβ from its precursor APP [146] and we have 
observed similar results in our study. However, through this study we have attempted to 
further characterize the mechanism by which DHA mitigates APP-induced metabolic 
changes by profiling the metabotypes associated with DHA-treated and untreated wild 
type and APP695 cell models and our findings suggested that DHA possibly acts by 
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mitigating APP-induced deregulations in glucose metabolism, TCA cycle, steroid and 
fatty acid biosynthesis. 
 
4.4.1 Effect of DHA on APP impaired energy metabolism pathways 
GC/TOFMS characterization of CHO-wt and CHO-APP695 at 24 h yielded distinct 
metabotypes associated with the DHA-treated CHO-APP695 cells. With DHA treatment, 
we found elevated levels of citric acid, succinic acid and malic acid and decreased levels 
of fumaric acid in CHO-APP695 cells suggesting a possible mitigation of APP-perturbed 
TCA enzyme activities commonly observed in AD patients [150]. Upregulation of the 
decreased PDH enzyme level in CHO-APP695 cells to the basal level of CHO-wt cells 
further corroborated the DHA-effected changes in the metabolite levels. In addition, level 
of glycine was also found to be elevated upon DHA treatment. Glycine, an amino acid, is 
required along with succinyl-CoA for the synthesis of porphyrins and efficient 
functioning of the ETC. Furthermore, levels of fructose and 3-phosphoglycerate, having 
important roles in glucose metabolism, were also found to be elevated with DHA 
treatment. Our findings suggested that DHA possibly mitigates APP-suppressed 
mitochondrial activity and associated hypometabolism of the CHO-APP695 cells, thus 
enabling them to recover from the metabolic perturbations.  
 
4.4.2 Effect of DHA on cholesterol metabolism 
There is a growing consensus underlying the mechanistic link between the formation of 
amyloid plaques and cholesterol metabolism [154]. Even though the effect of cholesterol 
on production of Aβ and metabolism is not yet completely defined, Barrett et al recently 
reported that APP has a flexible transmembrane domain that can bind cholesterol and 
form an avid complex leading to enhanced amyloidogenesis [155]. It is also believed that 
the membrane cholesterol content serves as a pro-amyloidogenic factor, governing the 
66 
 
activity of the enzymes playing a role in amyloidogenic processing of APP to Aβ [156-
159]. Apart from cholesterol, the oxidized products of cholesterol called oxysterols have 
also been studied for their possible role in the disease pathogenesis, due to their 
involvement in cholesterol regulation. In addition, in vivo studies carried out using statins 
[156] and other cholesterol lowering drugs in AD models have reported the therapeutic 
effect of lowering cholesterol content in diminishing Aβ deposition and Aβ load of the 
brain [160,161]. Increased consumption of PUFAs (notably the omega-3 family) has been 
associated with the reduction of risk in developing AD by lowering cholesterol levels. 
Levels of zymosterol, a precursor to cholesterol synthesis, cholesterol and cholesta-3, 5–
diene, an oxysterol, were found to be reduced in CHO-APP695 cells as compared to CHO-
wt with DHA treatment. As acetyl CoA is a common precursor and link between the 
TCA cycle and the cholesterol biosynthesis pathway, the question whether more acetyl 
CoA is being diverted towards energy metabolism pathways in the presence of DHA and 
thus reducing its availability for cholesterol synthesis, still remains to be answered. These 
results show that DHA plays a role in reducing cholesterol biosynthesis which is a 
potentially AD-preventive mechanism as demonstrated by cholesterol-lowering statins. 
 
4.4.3 Effect of DHA on fatty acid metabolism 
The possible contribution of inflammation in the etiology and pathogenesis of AD has 
been questioned over for many years now. Several pharmacological approaches have 
been proposed to control these inflammatory responses in order to prevent destruction of 
the viable tissues in an AD brain. Arachidonic acid, an omega-6 fatty acid, precursor to 
various pro-inflammatory and inflammatory molecules, has been postulated to be an 
important mediator of inflammation related damages in AD [162-164]. Arachidonic acid 
mediated inflammation has been reported to induce tau protein polymerization [165] and 
enhance generation of reactive oxygen species. A direct role of arachidonic acid in the 
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pathogenesis of AD was highlighted in a study conducted using positron emission 
tomography (PET) on brains of live, non-anaesthetized humans [166], where compared to 
their age matched controls, an elevated arachidonic acid metabolism was reported in AD 
patients. On the contrary, endogenous level of DHA was found to be significantly 
reduced in the brains of AD patients. As DHA and its metabolites have been known to 
exhibit anti-inflammatory activities, this reduction in the levels of DHA in AD patients 
may lead to further aggravation of the inflammation mediated damages in AD brain. 
 
We found that treatment with DHA resulted in a reduction in the endogenous levels of 
arachidonic acid in CHO-APP695 cells as compared to CHO-wt. On the other hand, DHA 
levels were found to be increased in lysate of CHO-APP695 cells post-treatment. This 
increase in DHA levels shows that DHA is indeed absorbed by the cells and the other 
results obtained are due to the effects mediated by DHA. Both omega-3 and omega-6 
fatty acids share the same biosynthetic pathway and compete for the pathway enzymes 
and incorporation into the cell membranes. Dietary consumption of DHA would result in 
a displacement of arachidonic acid from the cell membranes and serve as a precursor for 
the synthesis of anti-inflammatory metabolites, such as resolvins and protectins. Since 
enzymatic metabolism of arachidonic acid generates inflammatory mediators, decreased 
levels of arachidonic acid would also imply a decrease in the generation of its 
downstream metabolites and thus, a reduction in the damages mediated by ensuing 





GC/TOFMS-based metabonomic profiling approach served as a sensitive and powerful 
tool for identification of discriminant metabolites associated with control and DHA-
treated CHO-wt and CHO-APP695 cells. The metabolites identified were mainly involved 
in TCA cycle, glucose metabolism, cholesterol metabolism and arachidonic acid 
metabolism pathways. Our study provides an understanding of the metabolic changes 
induced by APP trafficking in the mitochondrial matrix and the mechanism by which 
DHA helps in mitigating these disturbances and restores the metabolic homeostasis of the 
mitochondria at an early stage. In addition, the preliminary effect of DHA on cholesterol 
metabolism fuelled the need to dive deeper into the mechanistic effects of DHA on the 
cholesterol metabolism pathway, which will be discussed in the next chapter. 
Considering DHA is clinically effective in improving cognitive functions at an early 
stage of AD [79,167] it may become a potential prophylactic agent for delaying the 
progression of this multi-factorial disease. In the same light, our findings will provide 
concurrent insights towards conceptualizing effective therapeutic outcomes using DHA 




CHAPTER 5: TARGETED METABONOMIC PROFILING OF CHOLESTEROL 
METABOLISM PATHWAY IN A DHA-TREATED ALZHEIMER’S DISEASE 




In Chapter 4, we have described the effects of DHA in mitigating APP-induced metabolic 
perturbations in an AD cell model. One of the key pathways found to be affected by 
DHA treatment was the cholesterol metabolism pathway. Although the exact link 
between cholesterol and Aβ production has not been conclusively defined, several 
evidences are available supporting the role of cholesterol in mediating the pathogenesis 
of AD. On the other hand, though several researchers have correlated the effect of DHA 
to that of the cholesterol lowering drug statins, no reports were available explaining its 
role in regulating the entire cholesterol metabolism pathway in AD. As such, this Chapter 
is focussed on elucidating the effect of DHA on cholesterol metabolism in an AD cell 
model using targeted metabonomics platform. 
 
Since 1994, when Sparks et al first provided the evidence of an increase in Aβ production 
by brain cholesterol levels [168], discussions have been going on to understand the link 
between the two. Subsequently, various researchers have helped to shed some light on the 
mechanistic interactions between cholesterol and APP or Aβ and several mechanisms 
have been proposed to explain the same. First, the ε4 allele of the ApoE gene coding for 
the lipid transporter protein – apolipoprotein E, has been identified as one of the major 
risk factors of AD and has been associated with increased cholesterol accumulation 
[30,169]; Second,  several epidemiological studies have linked hypercholesterolemia with 
increased risk of AD [169,170]; Third, cholesterol has been reported to modulate the 
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amyloidogenic processing of APP to Aβ by binding to the C99 transmembrane carboxyl-
terminal domain of APP. This binding increases the activity of BACE1 and γ-secretases 
enzymes on APP and reduces non-amyloidogenic APP processing through  decreased α-
secretase activity [171]; Fourth, by enabling orderly packing of the sphingolipids and 
gangliosides, cholesterol provides structural stability to lipid rafts, where γ- and β-
secretases are lodged and proteolytically cleave APP to Aβ [172]; Fifth, cholesterol acts 
as a cofactor to enhance APP substrate recognition by amyloidogenic processing 
enzymes [171]; Sixth, the breakdown products of cholesterol metabolism, oxysterols, 
mainly 24-hydroxycholesterol and 27-hydroxycholesterol, are known to mediate toxic 
damages to the neuronal cells and their concentrations are also reported to be elevated in 
AD patients [173,174]; Seventh, cholesterol is reported to accumulate in senile plaques 
and tangles of AD patients, serving as a “seed” required for deposition of aggregated Aβ 
and reducing its clearance to the periphery [175]; and last, by increasing the production 
of Aβ, cholesterol is also said to indirectly promote tau pathology, although the validity 
of this claim is being debated. Figure 5.1 summarizes these effects of cholesterol in 





Figure 5.1: Role of cholesterol in AD pathogenesis. ApoE allele ε4 and hypercholesterolemia are considered to be major risk factors of AD. Cholesterol 
promotes amyloidogenic activity of γ- and β- secretases and reduces the non-amyloidogenic processing by α-secretase. It also provides structural stability to lipid 
rafts housing these enzymes and promotes substrate recognition of APP by secretases, thus increasing Aβ production. Cholesterol indirectly increases NFT 
formation via Aβ production. The breakdown products of cholesterols, 24S-hydroxycholesterol and 27-hydroxycholesterol mediate neuronal cell toxicity.  
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Based on this role of cholesterol in AD pathology, several studies have been proposed to 
investigate the effectiveness of cholesterol-lowering drugs in mitigating AD. Amongst 
them, statins have been widely studied as they are the drug of choice for the long-term 
treatment of hypercholesterolemia for preventing cardiovascular diseases. Similar to 
statins, PUFAs, notably DHA, has also been reported to improve the overall cholesterol 
profile in hypercholesterolemic patients. For these reasons, it is logical to suggest that 
consumption of statins or DHA may ameliorate AD via improving the cholesterol profile. 
In fact, epidemiological studies have shown that statins or DHA intake increased 
cognitive function and potentially reduced the risk of developing AD in animal models 
[176-179]. However, clinical trials showed that both statins and DHA had no clinical 
benefit on patients who had already been diagnosed with AD [180-184]. This suggests 
that these compounds may be suitable as prophylactic agents rather than therapeutics for 
AD.  
 
Although the end effect of DHA in reducing cholesterol metabolism has been shown by 
us and others in their study, very little is known about the mechanism by which DHA 
exerts these effects. Nevertheless, several studies have compared the actions of DHA 
with that of statins. Statins are well-known inhibitors of 3-hydroxy-3-methyl-glutaryl-
CoA (HMG CoA), reductase the rate-limiting enzyme in the cholesterol synthesis 
pathway.  Similar to statins, Grimm et al also reported a direct inhibitory effect of DHA 
on HMG CoA reductase in human neuroblastoma cell line SH-SY5Y stably expressing 
human APP695 [185]. Their study also showed that DHA disturbed the normal distribution 
of cholesterol in the membrane by redistributing cholesterol from lipid rafts to the non-
raft domains, resulting in a decrease in the activity of β- and γ-secretases and Aβ 
production [186]. Moreover, anti-inflammatory and anti-oxidant activities of statins have 
also been compared with that of DHA [187]. Given the beneficial effects of DHA in 
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mitigating cholesterol, APP and Aβ mediated damages in AD, there is a need to 
investigate the mechanisms via which DHA perturbs deregulated cholesterol metabolism 
in AD. 
 
Thus, the overall goal of this chapter was to understand the mechanism of DHA in 
perturbing the cholesterol metabolism by identifying the key affected pathway 
components in a DHA-treated AD cell model. Similar to the previous chapter, we used 
CHO-wt and CHO-APP695 cells as our surrogate cells models. A GC/MS analysis method 
was developed and validated for the targeted profiling of cholesterol metabolites in our 
study. Figure 5.2 shows a general schematic of GC/MS based targeted metabolite 
profiling workflow adopted in this chapter. Figure 5.3 depicts the schematics of the 
cholesterol metabolism pathway and the metabolites of interest used in our study.  
 
Overall, our findings revealed the metabolic changes executed by DHA in the sterol 
biosynthesis segment of the cholesterol metabolism pathway. In addition to its effects on 
HMG CoA reductase enzyme, DHA may also possibly affect the activity of squalene 
epoxidase, the second important enzyme in the cholesterol metabolism pathway, to 
mediate the results the obtained. We believe that this study will further support the future 






Figure 5.2: The experimental workflow for GC/MS based targeted metabolite profiling of 











5.2 Materials and Methods   
5.2.1 Materials  
All reagents used for the work were of analytical grade. Silanization solution (5% 
dimethyl dichlorosilane in heptane), DMEM, cholesterol, isopentenyl pyrophosphate 
(IPP) trilithium salt, farnesyl pyrophosphate (FPP) ammonium salt, squalene, mevalonic 
acid lithium salt, 5α-cholestane and β-nicotinamide adenine dinucleotide phosphate 
reduced tetrasodium salt (NADPH) were obtained from Sigma-Aldrich (St Louis, MO, 
USA). Acetyl coenzyme A (acetyl CoA) sodium salt, HMG CoA trisodium salt, 
lanosterol, desmosterol, 7-dehydrocholesterol, 7β-hydroxycholesterol, lathosterol were 
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). 24S-
hydroxycholesterol, 27-hydroxycholesterol and zymosterol were obtained from Avanti 
Polar Lipids (Alabaster, Alabama, USA). DHA was purchased from Cayman Chemical 
Co. (Ann Arbor, MI, USA). FBS was purchased from Thermo Scientific Hyclone 
(Logan, UT, USA). Gibco® Penicillin-Streptomycin (10,000 U/mL) was purchased from 
Life Technologies (Carlsbad, CA, USA). MSTFA with 1% TMCS, and 2% MOX reagent 
were obtained from Pierce (Rockford, IL, USA). Ultra-pure grade PBS was purchased 
from 1st Base Private Limited (Singapore). DMSO, toluene and methanol were obtained 
from MP Biomedicals (Santa Ana, California, USA). Chloroform and hexane were 
purchased from Tedia Company, Inc. (Fairfield, OH, USA) and Fisher Scientific (Fair 
Law, NJ, USA), respectively. 
 
5.2.2 Cell culture  
CHO-wt and CHO-APP695 cells were cultured and maintained in a similar manner as 




5.2.3 Sample Preparation and Derivatization 
Both CHO-wt and CHO-APP695 cells were seeded at a density of 2 × 106 cells per 100 
mm plate. Following 24 h incubation at 37°C and 5% CO2 atmosphere, the cells were 
treated with 25 µM DHA. DMSO treatment was used as the vehicle control. The drug 
treatments were terminated after 24 h and the lysate samples were prepared in a similar 
manner as reported in Section 4.2.6 with some modifications. 10 µL of 150 µM 5α-
cholestane in chloroform was used as the internal standard in this study. 10 µL of the 
derivatized cell lysate samples were freshly diluted 10 times with hexane for cholesterol 
quantification prior to analysis. 
 
5.2.4 GC/MS metabolite profiling 
GC/MS analysis was performed on an Agilent 7890A Gas Chromatography coupled to a 
5975C inert MSD with Triple-Axis Detector (Agilent Technologies, Santa Clara, CA, 
USA). The primary column used was a HP-5MS 5% diphenyl- and 95% dimethyl-
polysiloxane (Agilent Technologies, Santa Clara, CA, USA) of internal diameter of 250 
µm, length of 30 m and film thickness of 0.25 µm. Helium was used as the carrier gas at 
a flow rate of 1 mL/min. The injection volume was 1 µL. A splitless injection was used 
for all samples. The optimized GC/MS front inlet and ion source temperatures were 250 
and 230°C, respectively. The oven temperature was set as follows: initial temperature 
120°C, increased to 180°C at 10°C/min, continued to be increased to 290°C at 50°C/min, 
and finally to 300°C at 50°C/min, where it was held for 10 min. The transfer line was 
maintained at 250°C. The MS was operated using an EI ionization source at -70 eV and a 
detector voltage of not more than 2800 V. The MS data were acquired using selected ion 
monitoring (SIM) experiments with an acquisition rate of 30 ms per ion.  The SIM 
experiment was optimized based on the mass-to-charge ratio (m/z) selected for 
quantitation and qualification of each metabolite. During preliminary screening, each 
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metabolite standard was analyzed separately and its mass spectrum was compared with 
that in the NIST library (Wiley registry, NJ, USA), FiehnLib, as well as literature papers, 
to select quantifying and qualifying m/z [188-191]. 
 
5.2.5 Preparation of Standard Samples 
A total of 15 metabolites as enlisted in Table 5.1, were included in the study.  
Table 5.1: Metabolites used in GC/MS -targeted metabolite profiling 
Compound Formula Mass 
Cholesterol C27H46O 458.00 
Acetyl CoA sodium salt C23H35O17N7P3S•Na3•H2O 809.57 
HMG CoA trisodium salt C27H41N7Na3O20P3S 977.62 
Mevalonic acid lithium salt C6H11O4 ·  xLi+ 202.00 
IPP trilithium salt C5H9Li3O7P2 263.89 
FPP ammonium salt C15H37N3O7P2 433.42 
Squalene C30H50 410.00 
Lanosterol C30H50O 498.00 
Zymosterol C27H44O 456.00 
Desmosterol C27H44O 456.00 
7-dehydrocholesterol C27H44O 456.00 
7β-hydroxycholesterol C27H46O2 546.00 
Lathosterol C27H46O 458.00 
24S-hydroxycholesterol C27H46O2 546.00 
27-hydroxycholesterol C27H46O2 546.00 
5α-cholestane (IS) C27H48 372.00 
Standard stock solutions containing 1 mg/mL of the metabolites and the IS were made in 
chloroform, except for salts which were prepared in water. All standard stock solutions 
were stored at −20°C. A series of working solutions were obtained by diluting 
appropriate amounts of these standards with either chloroform or water to different 
concentrations and stored at -20°C. Standards were diluted in 200 µL of culture medium 
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and derivatized in a similar manner as reported in Section 4.2.6 with 10 µL of 150 µM 
5α-cholestane in chloroform as IS.  
 
5.2.6 Method Validation 
US-FDA guidelines for bioanalytical method validation and International Conference on 
Harmonization (ICH) guidelines on analytical method validation with suitable 
modifications were followed for the method validation studies [192,193]. During method 
validation, parameters such as selectivity, sensitivity, linearity, accuracy and repeatability 
were investigated. Calculations of method validation results were carried out using the 
Microsoft Excel 2010 software. 
 
5.2.6.1 Selectivity 
Selectivity of the developed GC/MS method was investigated by comparing the 
chromatograms of blank and standard samples. The blank sample comprising 200 µL of 
cell culture medium was subjected to sample preparation as described earlier. The 
standard sample containing all the standard metabolites at 150 µM concentration was 
used for checking background chromatographic interferences, if any. 
 
5.2.6.2 Sensitivity 
The lower limit of quantification (LLOQ) was defined as the lowest concentration level 
that provided a peak area with a S/N ratio > 10, with precision of ±20%. In addition to the 
determination of the LLOQ of individual metabolites, it was important to determine the 
minimal amount of cell lysate that was required to produce a reasonably sensitive 
profiling of endogenous metabolites. In our method development, different cell seeding 
densities were analyzed to determine an optimal sensitivity limit of the GC/MS assay.  
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5.2.6.3 Linearity  
Due to the unavailability of metabolite-free ‘blank’ matrix, the standard addition method 
was adopted to study linearity in our assay. The calibration standards were prepared by 
spiking standard metabolites into 200 µL aliquots of blank cell culture medium and then 
subjecting them to sample preparation as described earlier. At least six concentrations 
were used for developing the calibration curve, the concentration range for which is given 
in Table 5.4. The concentrations of the metabolites in the calibration standards were 
calculated with reference to the 10 µM IS (5α-cholestane) by dividing the peak areas of 
the metabolites with that of IS. The resulting ratios were plotted against nominal 
concentration to construct calibration curve for each metabolite.  
 
5.2.6.4 Accuracy 
The accuracy was evaluated by analyzing three replicates of three QC samples: low, 
medium and high QC (LQC, MQC and HQC, respectively). The concentrations used at 
LQC, MQC and HQC for respective metabolites are indicated in Table 5.5. QC samples 
were analyzed using the constructed calibration curves to determine the concentrations. 
Stock solutions for calibration and accuracy standards were prepared independently. The 
accuracy of the developed method was determined by back calculation and measuring the 
percentage deviations of the measured concentrations from the nominal concentrations, 
with a range between 85% and 115% considered as acceptable. 
 
5.2.6.5 Repeatability  
Repeatability or intra-assay precision was evaluated using three replicates of each 
standard concentration analyzed under the same operating condition over a short period 
of time. A percentage deviation within ±15% was considered acceptable except at LLOQ 
where it was kept at ±20%. 
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5.2.7 Data Processing 
Data processing of the chromatograms obtained from GC/MS analysis was carried out 
using the MSD ChemStation (Version E.02.01.1177, Agilent Technologies, Santa Clara, 
CA, USA). Once the GC/Single quadrupole MS method was optimized, during 
subsequent sample analysis, each metabolite was identified using qualifying m/z chosen 
in the SIM mode and by comparing its retention time with that of its standard. The area of 
each peak in the samples was calculated using the quantifying m/z. The response ratio of 
each metabolite to internal standard was calculated and converted to concentration of the 
metabolite using the equation obtained from the calibration curve. Statistical comparison 
of metabolite levels between CHO-wt and CHO-APP695 was carried out using 
independent t-test with Welch’s correction, with a p-value of less than 0.05 considered to 
be statistically significant. Differences in the levels of metabolites between the treatment 









 and values >1 and <1 represented higher and 
lower metabolite levels observed in that treatment group, respectively. 
 
5.2.8 HMG CoA reductase and squalene epoxidase enzyme assay 
The enzyme assay was modified from the commercial available kits and was based on the 
spectrophotometric measurement of the decrease in absorbance of NADPH cofactor at 
340 nm, which represents the oxidation of NADPH by the catalytic subunit of the 
enzyme in the presence of a suitable substrate. Both CHO-wt and CHO-APP695 cells were 
seeded at a density of 3 x 106 per 10 mL in a T75 flask followed by treatment with 1 µM, 
10 µM and 25 µM DHA or DMSO as vehicle control. The cells were harvested 24 h post 
treatment and lysed in lysis buffer containing 1% Triton with protease inhibitor (Roche, 
Mannheim, Germany). Each cell lysate mixture was centrifuged at 13000g for 10 min at 
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4°C and protein concentration of the soluble extract was determined by Bradford protein 
assay. The assay was conducted using 100 µg of protein per sample, 400 µM of either 
HMG CoA or squalene as substrate, 400 µM of NADPH as co-factor and phosphate 
assay buffer (0.15 M, pH 7) up to a final volume of 200 µL per well in a 96-well plate 
format in duplicate. HMG CoA was used as a substrate for HMG CoA reductase whereas 
squalene was used as a substrate for conducting squalene epoxidase assay. A control 
sample without any substrate addition was also included in the assay as blank control. 
The final enzyme activity was assessed by measuring the reduction of NADPH to NADP+ 
at 340 nm using Infinite® 200Pro spectrophotometer (Tecan, Crailsheim, Germany). The 
slope of the generated scatter plot for NADPH reduction was used for evaluating the 
effect of DHA in inhibiting the enzyme activity. Statistical analysis was done via 
ANOVA with Dunnett’s post-hoc analysis, with *p<0.05, **p<0.01 and ***p< 0.001 
considered to be statistically significant. 
 
5.3 Results  
5.3.1 Sample Preparation and rationale for selected metabolites 
Since proper isolation of steroids from the biological matrix in their native state is 
essential before conducting quantitative analysis, organic solvent extraction method was 
initially explored to optimise the metabolite extraction from the samples as compared to 
simple ball milling procedure described in Section 5.2.3. The method tested was adopted 
from Acimovic J et al [188] which was mainly hydrolysis of cell samples followed by 
solvent extraction. Briefly, the samples were incubated with chloroform/methanol 2:1 v/v 
solution for 24 h, followed by hydrolysis with sodium hydroxide solution in ethanol and 
double extraction with cyclohexane. However, the organic solvent extraction method was 
tedious and time-consuming while yielding no significant difference in extraction 
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efficiency as compared to the ball milling method. Therefore, ball milling method was 
chosen as the sample preparation method in this study. 
 
15 metabolites in the cholesterol metabolism pathway were initially selected for this 
study and the rationale for their selection is stated in Table 5.2. However, acetyl CoA, 
HMG-CoA, IPP and FPP were excluded during the method optimization stage as they 
were not derivatisable using our method. 
 
Table 5.2: Rationale for metabolite inclusion in the study 
Metabolite Rationale 
Acetyl CoA Starting precursor for cholesterol synthesis  
HMG-CoA Key intermediate for cholesterol synthesis  
Mevalonate Product of rate-limiting enzyme, HMG-CoA reductase  
IPP Essential for synthesis of isoprenoids having roles in 
various cellular functions, eg: cell survival, GTPases  FPP 
Squalene Last non-steroidal intermediate and substrate of  squalene 
epoxidase, the second rate-limiting enzyme  
Lanosterol First intermediate sterol moiety in the cholesterol 
synthesis pathway 
Zymosterol 
Intermediates in cholesterol synthesis pathway, widely 




Cholesterol Promotes Aβ production in the brain  
27-hydroxycholesterol 
Main oxysterols (breakdown products of cholesterol) 






5.3.2 GC/MS Metabolite Profiling 
The optimized retention time, quantifying m/z and qualifying m/z of each metabolite 
standard and 5α-cholestane are summarized in Table 5.3. The SIM chromatogram of a 
mixture of 11 metabolite standards and 5α-cholestane at a concentration of 150 µM is 
shown in Figure 5.4(a). Desmosterol and 7-dehydrocholesterol were eluted at similar 
retention times (0.05 min difference in retention time); however, using the ions at m/z 343 
for the assay of desmosterol and the ion at m/z 325 for 7-dehydrocholesterol, provided a 
sufficient discrimination between these two sterols. Similarly, lathosterol and zymosterol 
were eluted at the similar retention times. Nevertheless, the two sterols were sufficiently 
discriminated using molecular ion of lathosterol at m/z 458 and the molecular ion of 
zymosterol at m/z 441.  
Table 5.3: Retention times, quantifying m/z and qualifying m/z of metabolite 
standards and internal standard 







Mevalonate 5.50 30 115 145 143 
Squalene 10.37 30 137 136 121 
5α-cholestane 10.72 30 217 149 357 
Cholesterol 12.25 30 329 129 368 
Desmosterol 12.52 30 343 351 129 
7-dehydrocholesterol 12.57 30 325 351 143 
Lathosterol 12.70 30 458 255 459 
Zymosterol 12.75 30 441 129 351 
7β-hydroxycholesterol 12.83 30 457 456 73 
Lanosterol 13.83 30 393 109 483 
24S-hydroxycholesterol 14.32 30 145 413 159 




Since the abundance of cholesterol in the cell lysate samples was very high, the 
cholesterol peak obtained from the chromatogram appeared saturated and resulted in an 
inaccurate quantification of cholesterol in the cell lysates. To overcome this limitation, 
several variations were explored to improve cholesterol’s peak shape. The methods 
attempted included split ratios and dwell time variations and dilution of an aliquot of the 
derivatized cell lysate with derivatizing agents (MOX reagent and MSTFA with 1% 
TCMS) or hexane. Amongst the tested methods, 10 times dilution with hexane was 
chosen as the method for analyzing cholesterol as it was economical and produced high-
quality symmetrical peak shapes. A representative overlay of chromatograms of 
cholesterol in CHO-APP695 and CHO-wt cell lysates treated with DHA and vehicle 
control is shown in Figure 5.4(b). A similar representative chromatogram for the other 













Figure 5.4: Representative GC/MS chromatograms. (a) SIM chromatogram of a mixture of 11 
metabolite standards and 5α-cholestane at a concentration of 150 µM; (b) Representative 
chromatogram overlay of cholesterol in DHA- and vehicle-treated CHO-APP695 and CHO-wt cell 
lysates; (c) Representative chromatogram overlay of the other  metabolites in DHA- and vehicle-
treated CHO-APP695 and CHO-wt cell lysates. 
  
5.3.3 Validation of GC/MS Method 
5.3.3.1 Selectivity 
The developed GC/MS method was found to be selective with regards to all the 
metabolites, as considerable interferences were not observed when a blank sample was 
compared with a sample containing all the standard metabolites. The high selectivity of 
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the method was pertinent to ensure that the profiled metabolites were derived from 
endogenous steroids and not other impurities; and the observed perturbations in the levels 




The LLOQ for the metabolites was found on the basis of a S/N > 10 and is listed in Table 
5.4. The precision at quantitation limit for all metabolites was found to be within the limit 
of ±20%. These results suggest that our method was sufficiently sensitive as the profiled 
endogenous levels of steroids in the cell lysates were well above the respective LLOQs. 
 
5.3.3.3 Linearity 
The GC/MS method was validated over different calibration ranges for the metabolites. 
All the analytes showed satisfactory linearity of response as evident from their average 
correlation coefficients of greater than 0.98 (Table 5.4). 
Table 5.4: Concentration range, linearity and LLOQ of the analyzed metabolites 
Metabolite Concentration range (µM) 




Mevalonate 0.1 – 100 0.996 0.1 
Squalene 0.1 – 10 0.984 0.1 
Cholesterol 100 – 5000 0.991 100 
Desmosterol 5 – 1000 0.980 5 
7-dehydrocholesterol 1 – 100 0.982 1 
Lathosterol 0.005 – 10 0.986 0.005 
Zymosterol 0.5 – 100 0.982 0.5 
7β-hydroxycholesterol 0.001 – 10 0.995 0.001 
Lanosterol 0.5 – 100 0.988 0.5 
24S-hydroxycholesterol 0.1 – 10 0.981 0.1 




The accuracy of the developed method was found to be satisfactory as the percentage 
deviations of the observed concentrations of the LQC, MQC and HQC samples from the 
nominal concentrations were all within the acceptable range of 85% to 115% for all the 
metabolites (Table 5.5). 
Table 5.5: Accuracy of the developed method 
Metabolite Theoretical conc. (µM) Accuracy (%)a 
Mevalonate 
LQC 0.5 100.7 
MQC 7 98.2 
HQC 50 110.2 
Squalene 
LQC 0.3 96.5 
MQC 2 98.8 
HQC 8.5 93.7 
Cholesterol 
LQC 200 86.7 
MQC 1500 110.5 
HQC 4500 106.4 
Desmosterol 
LQC 7 110.1 
MQC 150 102.1 
HQC 800 103.8 
7-dehydrocholesterol 
LQC 3 94 
MQC 12 99.5 
HQC 75 105.1 
Lathosterol 
LQC 0.07 99.7 
MQC 2 96.3 
HQC 8.5 108.4 
Zymosterol 
LQC 2 97.7 
MQC 17 105.6 
HQC 75 107.6 
7β-hydroxycholesterol 
LQC 0.05 94 
MQC 2 88.7 
HQC 8.5 101.3 
Lanosterol 
LQC 0.8 101.5 
MQC 6 88.5 
HQC 18 108.2 
24S-hydroxycholesterol 
LQC 0.2 97.3 
MQC 2 96.9 
HQC 8.5 94.9 
27-hydroxycholesterol 
LQC 3 97.3 
MQC 11 102.8 
HQC 22.5 96.6 
a 
 x100
ionconcentrat   ltheoretica











The precision was determined by computing the relative standard deviations or 
coefficient of variance (%CV) for repeatability at each concentration of the calibration 
standards. They were within the acceptable range of ±15%, except at LLOQ where it was 
±20%. %CVs are presented in Table 5.6. 
 
5.3.4 Effect of DHA treatment on cholesterol metabolism pathway  
Of the 11 metabolites analyzed, only 10 metabolites were detected in the lysate samples 
of CHO-wt and CHO-APP695 cells. Mevalonate, squalene, lanosterol, zymosterol, 
desmosterol, lathosterol, 7-dehydrocholesterol, cholesterol, 7β-hydroxycholesterol and 
27-hydroxycholesterol were amongst the list of detected metabolites, whereas, 24S-
hydroxycholesterol was not detected. One of the possible reasons may be the very low 
concentration of 24S-hydroxycholesterol in the samples to be accurately quantitated by 
the developed method. Differences in the levels of metabolites between the DHA- and 
vehicle-treated CHO-wt and CHO-APP695 cells are represented by fold changes and 
summarised in Table 5.7. As shown, the levels of all the detected metabolites were found 
to be significantly lowered in DHA-treated samples, except 7β-hydroxycholesterol for 
which no significant difference was observed between the two treatment groups.  
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Table 5.6: Repeatability or intra-assay precision of the developed method 
































































































   
   
   
   
   
   
   
a %CV is the percentage ratio of the standard deviation to the mean of the normalized peak area at the given concentration. 
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Concentration (µM)a Fold ∆b 
 CHO-wt CHO-APP695 CHO-wt CHO-APP695 
Mevalonate 35.04 ± 7.74 35.84 ± 3.13
 
ns
 1.02 41.45 ± 6.23 32.76 ± 4.10* 0.79 
Squalene 0.18 ± 0.03 0.25 ± 0.04* 1.38 0.28 ± 0.02 0.25 ± 0.04 ns 0.90 
Cholesterol 857.09 ± 45.51 968.16 ± 83.94* 1.13 931.80± 77.35 892.42 ± 81.89* 0.96 
Desmosterol 62.16 ± 6.74 76.43 ± 9.52* 1.22 44.29 ± 3.90 48.24 ± 5.69 ns 1.09 
7-dehydrocholesterol 2.07 ± 0.20 2.51 ± 0.32* 1.22 1.69 ± 0.19 1.86 ± 0.20 ns 1.10 
Lathosterol 0.05 ± 0.01 0.05 ± 0.01 ns 1.09 0.08 ± 0.06 0.06 ± 0.02 ns 0.76 
Zymosterol 6.28 ± 0.55 8.05 ± 0.90* 1.28 4.87 ± 0.53 5.69 ± 0.60* 1.17 
7β-hydroxycholesterol 0.07 ± 0.01 0.07 ± 0.01 ns 0.88 0.08 ± 0.01 0.07 ± 0.01 ns 0.90 
Lanosterol 0.77 ± 0.24 1.39 ± 0.21* 1.80 0.98 ± 0.21 1.56 ± 0.28* 1.58 
27-hydroxycholesterol 7.72 ± 1.1 4.99 ± 0.76* 0.65 5.95 ± 0.89 3.27 ± 0.45* 0.55 
a Concentration values of the metabolites calculated from the respective calibration curves and expressed as mean ± S.E.M. 
b Fold change (∆): CHO-APP695 (treatment) / CHO-wt (treatment). 
* p<0.05 and ns not significant when calculated using the independent t-test with Welch’s correction for concentration of metabolite in CHO-APP695 
cells compared to CHO-wt cells for respective treatment groups. 
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5.3.5 Effect of DHA on HMG CoA reductase and squalene epoxidase enzyme 
activity  
We conducted NADPH based enzyme assay to understand the effect of DHA on the 
activity of two important rate limiting enzymes of the cholesterol metabolism 
pathway, namely HMG CoA reductase and squalene epoxidase. Both these enzymes 
use NADPH as a co-factor to convert HMG CoA to mevalonic acid and squalene to 
2, 3-oxidosqualene, respectively. The assay was conducted by monitoring the 
reduction in NADPH absorbance at 340 nm and comparing the slope of reduction 
among the samples. For both the assays, a blank control without any substrate 
addition was also used for monitoring non-specific reactions of NADPH with other 
components of cell lysate. As shown in Figure 5.5(a) and (b), a decrease in the slope 
of NADPH absorbance was noted with increasing concentration of DHA treatment 
for both CHO-wt and CHO-APP695 cells. The slope of the blank control was noted to 
be very insignificant which indicated that NADPH was not utilized for non-specific 
reactions by other cell lysate components. The extent of HMG CoA reductase enzyme 
inhibition was significantly higher in CHO-APP695 cells as compared to CHO-wt 
(Figure 5.5(a)). However, no statistically significant difference was observed 
between the two cell types in the extent of squalene epoxidase enzyme inhibition by 







Figure 5.5: DHA treatment inhibits HMG CoA reductase and squalene epoxidase 
enzyme activity in a dose-dependent manner. Effect of DHA in inhibiting (a) HMG CoA 
reductase and (b) squalene epoxidase enzyme activity was investigated by monitoring the 
slope of reduction in NADPH absorbance at 340 nm. Values are mean ± SEM from three 
independent experiments. . */$/#p< 0.05, **/$$p< 0.01 and ***/$$$p<0.001, *compared to vehicle-
treated CHO-wt cells, $compared to vehicle-treated CHO-APP695 cells and # compared to 25 
µM DHA treated CHO-wt cells. 
 
5.4 Discussion 
There is an increasing body of evidence reporting deregulated cholesterol metabolism 
to be responsible for amyloid cascade hypothesis and tau pathology of AD. An 
opposite effect of APP and Aβ in deregulating cholesterol homeostasis has also been 
reported in some studies. Although the mechanism of cholesterol and APP/Aβ 
deregulations are yet to be elucidated, several epidemiological studies have shown 
that lipid-lowering agents, mainly statins, can reduce the risk of developing AD in 
elderly population [194,195]. Besides statins, PUFAs have also been reported for 
their possible interaction with the cholesterol metabolism pathway [196]. These 
actions of DHA have garnered significant interest in the use of lipidomics based-
approaches for elucidating its role in regulating cholesterol metabolism and 
homeostasis. As such, through this study, we have attempted to characterize the effect 
of DHA on cholesterol metabolism by using targeted metabonomics platform in a 
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DHA-treated AD cell models. Our results showed that the levels of mevalonic acid, 
squalene, lanosterol, zymosterol, desmosterol, lathosterol, 7-dehydrocholesterol, 
cholesterol and 27-hydroxycholesterol decreased with DHA treatment in diseased 
APP695-associated cell model as compared to the healthy wild type cells.  
 
As shown in Figure 5.2, HMG CoA reductase is the first rate limiting step of the 
cholesterol metabolism pathway and similar to statins, DHA has already been 
reported to directly inhibit the activity of this key enzyme. We observed similar 
inhibitory effect of DHA in our HMG CoA reductase enzyme assay. Since mevalonic 
acid is the primary product of HMG CoA reductase activity, a decrease in the levels 
of mevalonic acid upon DHA treatment is expected.  Reduction in the synthesis of 
mevalonate has two-pronged effect; it not only affects the sterol-mevalonate pathway 
leading to generation of squalene and cholesterol, but also affects the non-sterol 
mevalonate pathway generating isoprenoids, mainly IPP, FPP and geranylgeranyl 
pyrophosphate (GGPP). These isoprenoids have been reported to be increased in the 
brains of AD patients [197] and involved in the regulation of APP metabolism [198]. 
Besides modulating Aβ production, a decrease in the generation of isoprenoids also 
causes a reduction in the levels of G-proteins such as Rho, Rab and Rap, 
subsequently leading to inactivation of NF-κB and associated inflammatory responses 
[199]. Thus, reduced activity of the non-sterol isoprenoids pathway may possibly be 
useful for facilitating the neuroprotective effects of DHA in AD, similar to mediating 
the neuroprotective, anti-cancer and anti-inflammatory effects of statins [200,201]. 
Due to the shortcomings of our method, we were not able to detect the levels of IPP 
and FPP in our study, but, detection of the changes in these isoprenoids levels with 
DHA treatment may provide conclusive answers to this phenomenon.  
 
The sterol-mevalonate pathway begins with the generation of squalene from FPP by 
the activity of the squalene synthase enzyme. The subsequent conversion of squalene 
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to cholesterol is mediated through a series of different intermediates and enzyme 
activities. With DHA treatment we found squalene levels to be reduced in CHO-
APP695 cells.  This effect may either be the result of lower amount of mevalonate 
substrate available for squalene generation or due to the added effect of DHA on 
squalene synthase besides HMG CoA reductase enzyme. Squalene epoxidase is the 
second rate limiting enzyme of cholesterol biosynthesis pathway. DHA treatment was 
found to reduce the activity of squalene epoxidase in a dose dependent manner.  This 
finding is of particular interest in developing hypocholesterolemic agents that 
specifically act on the sterol-mevalonate pathway while maintaining the activity of 
non-sterol-mevalonate pathway. To our knowledge, this is the first report of 
inhibition of squalene epoxidase activity by DHA treatment. This decrease in 
squalene epoxidase activity is also supported by lowered levels of other sterol 
intermediates, namely lanosterol, lathosterol, desmosterol, 7-dehydrocholesterol and 
zymosterol, with DHA treatment – an effect much similar to that of statins. All these 
intermediates have been reported to play significant roles in cholesterol metabolism 
or associated diseases. For example, lathosterol has been used as a marker of 
estimating the extent of endogenous cholesterol synthesis. Another intermediate, 7-
dehydrocholesterol is a highly oxidizable moiety that gives rise to free radical and 
toxic oxysterols. A decrease in 7-dehydrocholesterol levels with DHA treatment may 
imply a decrease in the generation of toxic oxysterols and subsequent decrease in 
oxidative stress mediated damages in AD. In fact, we did observe a decrease in the 
levels of cholesterol catabolite product- 27-hydroxycholesterol upon DHA treatment. 
27-hydroxycholesterol is a neurotoxic product reported to accumulate in the brains of 
sporadic AD patients and cause upregulation of Aβ production through increasing the 
activity of BACE1 and APP [202,203]. Contrary to the results of 27-
hydroxycholesterol, we did not see any effect of DHA treatment on 7β-
hydroxycholesterol level or detect any 24S-hydroxycholesterol in our cell samples. 
This may be due to the preferential breakdown of cholesterol through 27-
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hydrxycholesterol pathway, leading to very low generation of the other two 
oxysterols to allow for any detectable limits or noticeable changes.    
 
5.5 Conclusion 
To summarize, a GC/MS assay was successfully utilized in this chapter for the 
targeted profiling of important metabolites in the cholesterol metabolism pathway of 
an AD disease cell model. Our findings added details to the overall picture of the 
effects of DHA in modulating the sterol metabolism pathway in an AD cell model. 
The findings from this project lend further support for the use of DHA as a 
prophylactic agent for AD management. Besides AD, the effect of DHA in inhibiting 
HMG CoA reductase and squalene epoxidase enzyme activity makes it a suitable 





CHAPTER 6: CONCLUSION AND FUTURE PERSPECTIVES 
The overall aim of this thesis was to identify and explore potential novel modulators 
and targets for therapeutic intervention in AD. We tested two different hypotheses in 
our study. Our first hypothesis was focussed on investigating the synergistic effect of 
DHFR enzyme inhibition on the neuroprotective effects mediated by GSK-3β 
inhibitors in modulating AD pathogenesis. Our second hypothesis focussed on 
elucidating the molecular mechanism of DHA in mitigating APP-induced metabolic 
perturbations in energy and cholesterol metabolism pathways by characterizing and 
comparing the metabotypes of DHA-treated and untreated wild type and APP-
associated cells using metabonomics approach.  
 
In Chapter 3, we provided an important proof-of-concept that the combined use of 
DHFR and GSK-3β inhibitors enhanced the neuroprotective effects mediated by 
GSK-3β inhibition in modulating multiple pathophysiological pathways involved in 
the etiology of AD, namely cell survival, tau phosphorylation and inflammation. Pre-
treatment with the dual enzyme inhibitors was observed to increase the transcriptional 
and translational activities of β-catenin protein and Axin-2, and noted to improve cell 
survival by providing protection against H2O2 induced cytotoxic insults. The decrease 
in ROS and NO generation and TNF-α release was found to be even more 
pronounced with simultaneous inhibition of both the enzymes than inhibiting GSK-3β 
alone. Furthermore, a prominent decrease in tau hyperphosphorylation was also noted 
when the two enzymes were inhibited together.  
 
Although the dual enzyme inhibition strategy seems to be quite promising, few 
additional studies need to be conducted to confirm the clinical therapeutic potential of 
this strategy. Firstly, the mechanism of interaction between the folate and the GSK-
3β/β-catenin signaling needs to be elucidated. As briefly reported in Chapter 3, the 
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link between the two enzymes may possibly be PI3K or the insulin pathway. 
Nevertheless, further mechanistic studies need to be conducted to confirm whether 
the results obtained are due to an interaction occurring between the two pathways or 
due to a chance correlation altogether. Secondly, the combination concentration and 
the treatment duration of GSK-3β and DHFR inhibitors needs to be optimized as both 
these enzymes have essential roles in other cellular processes, over and above their 
involvement in AD pathogenesis. The challenge will not only be to optimize this 
strategy to result in sufficient selectivity but also to avoid detrimental side effects 
resulting from inappropriate disruption of either of the pathways. Thirdly, other 
selective GSK-3β inhibitors apart from BIO can be tested to see if they give better 
results with simultaneous DHFR inhibition as compared to BIO. Various potent and 
selective GSK-3β inhibitors are being developed and studies by various research 
groups [204-207] and these compounds should be tested for their synergism together 
with DHFR inhibition for neuroprotection. Fourthly, this dual enzyme inhibition 
strategy should be tested for its efficacy in reducing Aβ production and load. Our 
preliminary studies to measure the effect on Aβ40 release using ELISA did not yield 
any positive results, possibly due to lack of optimization in treatment duration and 
concentration or because Aβ is considered to be an event upstream of GSK-3β 
activity. Nevertheless, an optimized study, together with additional GSK-3β 
inhibitors should be conducted to assess the effectiveness of this strategy on Aβ 
production. Lastly, a follow-up study using appropriate animal models are required to 
confirm and supplement the findings of our study. Our in vitro results have been 
encouraging but the true therapeutic potential of this dual enzyme inhibition strategy 
will only become evident upon successful conduction of in vivo experiments in AD 
animal models. 
 
In Chapter 4, we investigated the mechanism by which DHA mitigated APP-induced 
metabolic perturbations in AD cell model. Using GC/TOFMS analysis, we confirmed 
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the presence of mitochondrial dysfunctions in CHO-APP695 cells even before the 
release of detectable levels of Aβ40. Construction of robust PLS-DA models enabled 
for a distinct differentiation between the DHA- and vehicle-treated CHO-APP695 and 
CHO-wt cells. On the basis of these models, a set of discriminant marker metabolites 
were identified which were related to energy metabolism, cholesterol metabolism and 
fatty acid metabolism pathways. Treatment with DHA was noted to mitigate the 
perturbations in these marker metabolites levels and PDH enzyme activity. 
Furthermore, DHA was also observed to decrease the release of Aβ40 from the CHO-
APP695 cells upon prolonged treatment.  As a continuation of the global 
metabonomics study, we conducted targeted metabolite analysis of cholesterol 
pathway for understanding the effect of DHA on cholesterol synthesis and 
breakdown. In Chapter 5, we developed and validated a GC/MS method for 
simultaneous profiling of 11 key metabolites of the cholesterol metabolism pathway.  
DHA was observed to act in a manner similar to statins and the levels of key 
cholesterol anabolites and catabolites was found to be decreased in CHO-APP695 cells 
as compared to CHO-wt cells. The activity of HMG CoA reductase and squalene 
epoxidase enzymes was also observed to be reduced upon DHA treatment.  
 
The present metabonomics work has raised several issues and identified potential 
opportunities to be pursued in future investigations. Foremost, the study needs to be 
repeated in a primary neuronal cells or animal models. Although CHO-APP695 and 
CHO-wt cells have been widely used as AD cell models by other research groups 
[140-144]  and has also been validated by us using western blot and ELISA assays, 
the use of primary neuronal cells will be very valuable to support the study 
conclusions. However, the challenge associated with the use of primary cells is the 
difficulty in generating stable overexpression of APP as the metabolism deregulating 
agent. Other neuronal cell models with APP overexpression, for example SH-SY5Y 
or SK-N-BE cells cannot be used for the study as these cells are neuroblastoma cells. 
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As suggested by Gleissman et al, DHA undergoes a different metabolism between 
normal and tumour cells, giving rise to cytotoxic intermediates in tumour cells [208]. 
Thus, the final choice for the selection of a cell model will depend on the ease of APP 
overexpression and normal DHA metabolism. Besides in vitro models, APP 
overexpressing transgenic mice or patient samples may also be used to provide 
further validation to the results. Some clinical studies using metabonomics platform 
have already been conducted for understanding AD progression and identifying early 
stage disease biomarkers in patient samples [209] . However, no metabonomic studies 
have been carried out for understanding clinical drug response of DHA in AD 
patients. In addition, further biochemical assays need to be carried out apart from 
metabonomics study. We have already shown the effect of DHA in regulating PDH 
enzyme levels in CHO-APP695 cells, but additional enzyme assays will lend further 
validation our results.  Especially in the case of the targeted cholesterol 
metabonomics study, additional enzyme assays need to be conducted to identify the 
potential targets of DHA, besides HMG CoA reductase and squalene epoxidase. The 
effect of DHA on other important enzymes of the cholesterol biosynthesis pathway, 
such as squalene synthase and dehydrocholesterol reductase enzymes also needs to be 
evaluated. Additionally, further studies should be conducted to better understand the 
mechanism of action of DHA in inhibiting squalene epoxidase enzyme activity.  
 
In conclusion, the findings of this thesis have helped in identifying potential 
modulators of AD pathogenesis and will provide concurrent insights towards 
conceptualizing effective therapeutic outcomes from the two strategies for effective 
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Figure S1: Knockdown efficiency of DHFR siRNA in SH-SY5Y neuroblastoma cells. (a) 
SH-SY5Y cells were with either negative control siRNA or DHFR siRNA sequence A/B/C at 
10 nM and 20 nM concentrations and cell lysates were subjected to western blot analysis. The 
blots shown are representative of three different experiments; (b) Cellular DHFR protein 




Appendix B: Marker metabolites identified from medium and lysate samples of DHA-treated and vehicle-treated CHO-wt and CHO-APP695 cells. 








Normalized peak area (x 10-4)c Fold 
∆
d CHO-wt CHO-APP695 CHO-wt CHO-APP695 
Propanoic acid medium NIST 1032.0 97.6 ± 22.1 131.2 ± 11.2 * 1.34 83.0 ± 26.3 126.0 ± 16.6* 1.52 
Lactic acid medium NIST 1059.6 902.3 ± 10.4 1371.1 ± 49.1* 1.52 844.5 ± 94.6 1157.8 ± 36.1ns 1.37 
Alanine medium NIST 1100.2 280.3 ± 48.7 465.8 ± 70.1* 1.66 345.5 ± 75.2 568.9 ± 86.5* 1.65 
Oxalic acid medium NIST 1125.8 2.6 ± 0.1 2.9 ± 0.1* 1.12 2.5 ± 0.3 3.0 ± 0.3* 1.23 
Urea medium NIST 1221.3 65.5 ± 24.2 78.2 ± 20.7ns 1.19 88.2 ±19.7 114.3 ± 17.1* 1.30 
4-hydroxybutyric acid medium NIST 1234.8 2.8 ± 0.3 5.3 ± 1.1* 1.85 3.3 ± 0.2 5.5 ± 0.7* 1.68 
Niacin medium NIST 1269.8 0.4 ± 0.0 0.5 ± 0.0* 1.21 0.5 ± 0.0 0.6 ± 0.0* 1.34 
Glycerol medium NIST 1292.5 26.7 ± 2.1 32.9 ± 0.9* 1.23 24.6 ± 3.3 31.6 ± 1.4* 1.28 
Threonine medium NIST 1294.7 49.8 ± 12.7 53.5 ± 5.2 ns 1.07 61.3 ± 10.6 80.2 ± 12.6* 1.31 
Succinic acid medium NIST 1305.9 3.2 ± 0.5 3.5 ± 0.1 ns 1.09 3.4 ± 0.3 4.1 ± 0.3* 1.20 
Glycine medium NIST 1315.8 80.8 ± 20.9 102.1 ± 29.4 ns 1.26 181.4 ± 58.3 284.6 ± 47.6* 1.57 
Uracil medium NIST 1328.4 2.9 ± 0.2 4.1 ± 0.1* 1.41 2.9 ± 0.3 4.3 ± 0.2* 1.49 





Serine medium NIST 1373.9 11.9 ± 3.1 5.2 ± 1.0* 0.44 15.0 ± 0.4 5.4 ± 0.8* 0.36 
Aspartic acid medium NIST 1482.2 0.3 ± 0.1 0.5 ± 0.0 ns 1.67 0.5 ± 0.1 0.8 ± 0.2* 1.76 
Butylated hydroxytoluene medium NIST 1492.3 2.0 ± 0.0 1.3 ± 0.6 ns 0.65 1.7 ± 0.3 1.3 ± 0.1* 0.77 
Malic acid medium NIST 1501.2 1.3 ± 0.1 1.2 ± 0.3 ns 0.92 1.4 ± 0.1 1.6 ±0.1* 1.17 
Pyroglutamic acid medium NIST 1506.6 1043.4 ± 15.8 737.4 ± 43.9* 0.71 1197.2 ± 21.8 811.1 ± 12.0* 0.68 
Methionine medium NIST 1517.2 15.7 ± 4.3 12.2 ± 2.5 ns 0.77 17.1 ± 4.7 11.4 ± 0.8* 0.67 
Trihydroxybutyric acid medium NIST 1576.4 25.9 ± 3.7 27.6 ± 0.3 ns 1.06 24.0 ± 3.0 28.0 ± 1.8* 1.17 
Mannose medium NIST 1881.4 7.0 ± 3.0 3.3 ± 0.6 * 0.48 4.8 ± 2.1 2.2 ± 2.0ns 0.45 
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Fructose medium NIST 1927.7 278.2 ± 26.3 152.2 ± 20.1* 0.55 273.7 ± 22.6 146.2 ± 27.8* 0.53 
Mannitol medium NIST 2004.1 78.1 ± 6.1 79.0 ± 2.7 ns 1.01 73.0 ± 6.6 81.1 ± 5.1* 1.11 
Lactate lysate NIST 1059.8 0.8 ± 0.1 1.3 ± 0.2* 1.62 0.8 ± 0.2 1.6 ± 0.2* 1.89 
Oxalic acid lysate NIST 1121.3 9.0 ± 1.5 13.9 ± 3.4* 1.54 10.8 ± 1.5 16.4 ± 3.9* 1.52 
Norleucine lysate NIST 1149.8 92.0 ± 6.9 95.7 ± 3.0 ns 1.04 89.0 ± 2.0 101.2 ± 6.1* 1.14 
Hydroxylamine lysate NIST 1152.5 3.3 ± 0.3 3.3 ± 1.1 ns 1.01 3.6 ± 0.4 3.0 ± 0.2* 0.85 
Valine lysate NIST 1227.0 59.9 ± 17.7 70.7 ± 26.0 ns 1.18 78.0 ± 4.4 94.8 ± 8.9* 1.22 
Serine lysate NIST 1256.4 51.3 ± 4.1 26.3 ± 1.3* 0.51 56.6 ± 2.3 29.5 ± 1.7* 0.52 
Niacin lysate NIST 1272.9 1.2 ± 0.3 2.5 ± 0.5* 2.10 1.3 ± 0.2 2.2 ± 0.4* 1.77 
Glycerol lysate NIST 1294.7 32.6 ± 9.2 32.8 ± 2.3 ns 1.01 28.9 ± 2.0 32.4 ± 1.8* 1.12 
Threonine lysate NIST 1297.8 133.9 ± 7.0 134.0 ± 6.1 ns 1.00 144.0 ± 3.2 158.9 ± 6.7* 1.10 
Uracil lysate NIST 1330.7 1.5 ± 0.3 1.5 ± 0.6 ns 1.01 1.7 ± 0.2 2.1 ± 0.2* 1.19 
Itaconic acid lysate NIST 1336.6 2.9 ± 0.4 9.3 ± 1.1* 3.25 2.6 ± 0.2 9.4 ± 0.7* 3.62 
Aspartic acid lysate NIST 1415.2 91.7 ± 8.6 56.3 ± 3.8* 0.61 87.4 ± 5.5 47.9 ± 3.5* 0.55 
Malic acid lysate NIST 1501.6 20.5 ± 1.5 ns 21.6 ± 1.3* 1.05 16.6 ± 0.9 25.3 ± 1.7* 1.52 
N-acetylglutamate lysate NIST 1522.1 1282.9 ± 90.8 815.2 ± 70.0* 0.64 1068.2 ± 95.0 764.1 ± 74.6 * 0.72 
Threitol lysate NIST 1547.9 4.3 ± 0.4 6.1 ± 0.6* 1.42 4.9 ±0.2 7.8 ± 0.2* 1.60 
2,3,4-Trihydroxybutyric acid lysate NIST 1576.4 0.3 ± 0.1 0.6 ± 0.1* 2.05 0.4 ± 0.0 0.7 ± 0.0* 1.89 
2-Hydroxyglutaric acid lysate NIST 1584.4 4.9 ± 0.7 10.7 ± 1.1* 2.17 4.9 ± 0.6 12.2 ± 0.1* 2.49 
Ribitol lysate NIST 1796.7 3.4 ± 0.5 4.1 ± 0.7 ns 1.21 2.7 ± 0.3 3.4 ± 0.3* 1.29 
Citric acid lysate NIST 1844.0 7.5 ± 0.9 8.4 ± 3.3* 1.12 16.6 ± 1.5 29.6 ± 2.4* 1.99 
Myristic acid lysate NIST 1844.7 11.5 ± 1.4 13.6 ± 0.8* 1.19 13.9 ± 1.2 16.6 ± 1.2* 1.19 
Fructose lysate NIST 1928.1 16.0 ± 2.4 22.0 ± 2.7* 1.37 23.4 ± 2.1 31.6 ± 1.3* 1.35 
Myo-Inositol lysate NIST 2155.8 22.1 ± 2.0 34.6 ± 3.4* 1.57 25.5 ± 2.0 41.5 ± 2.3* 1.63 
Arachidonic acid lysate NIST 2352.5 3.0 ± 0.3 3.5 ± 0.4* 1.17 3.2 ± 0.1 2.7 ± 0.3* 0.85 
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11-Eicosenoic acid lysate NIST 2407.5 2.1 ± 0.2 2.2 ± 0.4 ns 1.04 2.3 ± 0.1 2.1 ± 0.1* 0.90 
Piceatannol lysate NIST 2521.1 0.7 ± 0.1 2.2 ± 0.4* 3.14 0.5 ± 0.1 1.7 ± 0.2* 3.44 
Docosahexaenoic acid lysate NIST 2552.3 3.2 ± 1.4 2.5 ± 0.7* 0.78 3.5 ± 0.2 4.5 ± 0.3* 1.29 
2-Monopalmitin lysate NIST 2575.8 22.8 ± 1.4 19.5 ± 2.2* 0.85 26.3 ± 0.7 20.5 ± 0.6* 0.78 
1-Monopalmitin lysate NIST 2599.4 48.5 ± 3.5 42.3 ± 4.3* 0.87 53.5 ± 3.5 41.9 ± 1.4* 0.78 
1-Monooleoylglycerol lysate NIST 2765.2 0.2 ± 0.1 0.3 ± 0.0* 1.39 0.2 ± 0.0 0.2 ± 0.0* 1.27 
Stearic acid lysate NIST 2792.5 72.7 ± 4.4 62.4 ± 4.8* 0.86 77.3 ± 6.6 59.5 ± 3.8* 0.77 
Uridine monophosphate lysate NIST 2836.0 0.3 ± 0.1 0.8 ± 0.3* 2.71 0.4 ± 0.1 0.7 ± 0.2* 1.63 
Cholesta-3,5-diene lysate NIST 2885.6 3.0 ± 0.3 3.1 ± 0.4 ns 1.05 3.0 ± 0.4 1.5 ± 0.5* 0.52 
Eicosanoic acid lysate NIST 2983.4 2.3 ± 0.2 1.9 ± 0.3* 0.83 2.7 ± 0.3 2.0 ± 0.1* 0.73 
Zymosterol lysate NIST 3202.0 4.3 ± 0.4 7.6 ± 0.9* 1.77 4.1 ± 0.3 6.6 ± 0.7* 1.59 
 
a Metabolite identification using standard compound or NIST library search. 
b Kovats RI refers to Kovats retention index 
c
 Normalized peak area values expressed as mean ± S.E.M. 
d
 Fold change (∆): CHO-AβPP695 (treatment) / CHO-wt (treatment). 
*
 p<0.05 and ns not significant when calculated using the independent t-test with Welch’s correction for normalized peak area of CHO-APP695 cells compared 
to CHO-wt cells for respective treatment groups. 
 
 
 
 
